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AGC Array Gene Centering 
AGEP Alignment of gene expression profiles 
AML Acute myeloid leukemia 
AvgDiff Average difference 
BLAST Basic Local Alignment Search Tool 
CDF-file Chip description file, describing the physical layout as well as as the 
probeset grouping of Affymetrix arrays 
cDNA Complementary DNA, usually DNA copy of mRNA. 
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EQ Equalization transformation 
EST Expressed sequence tags 
GEO Gene Expression Omnibus 
GIST Gastrointestinal stromal tumor 
GO-BP Gene ontology – biological processes 
HK Housekeeping gene based normalization 
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ICDO International classification of diseases for oncology 
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miRNA Short ribonucleic acid (RNA) molecule 
MM Mismatch (probe) 
mRNA Messenger ribonucleic acid (RNA) 
N-stage Stage of tumor in terms of invasion to lymph nodes 
NN Nearest neighbour 
PM Perfect match (probe) 
RMA Robust multichip average 
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SAGE Serial analysis of gene expression 
SMD Stanford Microarray Database 
SVM Support vector machine 
T-stage Stage of tumor in terms of size and invasion status to nearby tissues 
TM-score Tissue match score 
TS-score Tissue specificity score 
TTD Therapeutic Target Database 
WBL Weibull distribution based normalization 







Gene expression is one of the most critical factors influencing the phenotype 
of a cell. As a result of several technological advances, measuring gene 
expression levels has become one of the most common molecular biological 
measurements to study the behaviour of cells. The scientific community has 
produced enormous and constantly increasing collection of gene expression 
data from various human cells both from healthy and pathological conditions. 
However, while each of these studies is informative and enlighting in its own 
context and research setup, diverging methods and terminologies make it very 
challenging to integrate existing gene expression data to a more 
comprehensive view of human transcriptome function. On the other hand, 
bioinformatic science advances only through data integration and synthesis. 
The aim of this study was to develop biological and mathematical methods to 
overcome these challenges and to construct an integrated database of human 
transcriptome as well as to demonstrate its usage. 
 
Methods developed in this study can be divided in two distinct parts. First, the 
biological and medical annotation of the existing gene expression 
measurements needed to be encoded by systematic vocabularies. There was 
no single existing biomedical ontology or vocabulary suitable for this purpose. 
Thus, new annotation terminology was developed as a part of this work. 
Second part was to develop mathematical methods correcting the noise and 
systematic differences/errors in the data caused by various array generations. 
Additionally, there was a need to develop suitable computational methods for 
sample collection and archiving, unique sample identification, database 
structures, data retrieval and visualization. Bioinformatic methods were 
developed to analyze gene expression levels and putative functional 
associations of human genes by using the integrated gene expression data. 
Also a method to interpret individual gene expression profiles across all the 
healthy and pathological tissues of the reference database was developed. 
  
As a result of this work 9783 human gene expression samples measured by 
Affymetrix microarrays were integrated to form a unique human 
transcriptome resource – GeneSapiens. This makes it possible to analyse 
expression levels of 17330 genes across 175 types of healthy and pathological 
human tissues. Application of this resource to interpret individual gene 
expression measurements allowed identification of tissue of origin with 92.0% 
accuracy among 44 healthy tissue types. Systematic analysis of transcriptional 
activity levels of 459 kinase genes was performed across 44 healthy and 55 
pathological tissue types and a genome wide analysis of kinase gene co-
expression networks was done. This analysis revealed biologically and 
medically interesting data on putative kinase gene functions in health and 
disease. Finally, we developed a method for alignment of gene expression 
profiles (AGEP) to perform analysis for individual patient samples to pinpoint 
gene- and pathway-specific changes in the test sample in relation to the 
reference transcriptome database. We also showed how large-scale gene 
expression data resources can be used to quantitatively characterize changes 




Taken together, these studies indicate the power of systematic bioinformatic 
analyses to infer biological and medical insights from existing published 
datasets as well as to facilitate the interpretation of new molecular profiling 






Since the sequencing of the human genome by Istrael et al., Lander et al. and   
Venter et al. [1-3] there has been a rapid development of technologies 
enabling genome wide gene expression measurements as described by 
Schultze et al. [4]. The qualitatively and quantitatively increasing capability to 
analyze gene expression has greatly contributed towards our understanding of 
the functions of genes in health and disease. 
 
One of the most widely applied technologies to perform genome wide gene 
expression measurements is the Affymetrix GeneChip system, which is based 
on 25mer probes that are photolithographically synthesized on the surface of 
the chip. During the many years of manufacture and application of these 
GeneChips, they have been found to be robust and reliable as described by 
Dalma-Weiszhausz et al. and Shi et al. [5-7]. Furthermore, the scientific 
community has greatly contributed to further development of data handling, 
normalization and data analysis methods available for Affymetrix based data 
with the few most influential studies being done by Bolstadt et al., Faller et al., 
Irizarry et al., Schadt et al. and Workman et al. [8-12]. 
 
Constantly increasing amounts of gene expression data in public repositories 
as described by Edgar et al., Hubble et al. and Rocca-Serra et al. [13-15] would 
allow for a much more advanced analysis of the molecular profiles of cells. 
Efforts to integrate these data together have been hindered by various 
technical difficulties resulting from incompatible microarray technologies and 
methods related to them. However, the scientific community has performed 
various meta-analysis studies of microarray data, with most influential studies 
done by Day et al., Lee et al. and Rhodes et al. [16-20], partly overcoming 
these challenges by e.g. integrating the results obtained from the separate 
analysis of each of the studies. 
 
The two most fundamental challenges are caused by the mutual 
incompatibility of various microarray generations and the heterogeneous 
anatomical, medical and pathological nomenclature applied to the annotation 
of the biological samples. It seems that in any gene expression measurement 
technology relying on hybridization of complementary nucleotide sequences, 
considerable variability is caused by the effect of the specific nucleotide 
sequence on the hybridization characteristics. This is a major reason for 
incompatibility between microarray generations. Any study attempting to 
combine and integrate data from multiple experiments needs to take this issue 
into account. Annotation of the biological samples needs to be sufficiently 
similar so that biologically and medically equivalent samples can be identified 
and grouped together for the purpose of data analysis. The enormous 
complexity of biological organisms and the range of clinical conditions 
renders most computational annotation methods ineffective and furthermore 
requires multiple layers of manual annotation to provide biologically sensible 
representation of samples. 
 
Even though the layers of regulation of gene and protein expression and 




expression of genes is a key controller of cells’ higher-level behaviour. 
Expression of genes provides components for the entire regulation machinery 
and expression level changes are required for fundamental changes in a cell’s 
life.  There is an enormous amount of scientific knowledge linking expression 
levels of various genes to myriads of phenomena in both healthy and diseased 
cells and tissues. However, most of these data remain scattered and 
fragmented, the synthesis and ultimate “model” of the human transcriptome 
is lacking. 
 
However, if these challenges can be solved, the integration and synthesis of 
gene expression data provides novel possibilities to understand biological 
systems. For example, in order to identify a potential biomarker, one needs to 
be able to study the expression levels of the gene across the entire spectrum of 
tissues and diseases. Similarly, the association of an expression change of a 
gene to a specific disease or pathological state requires compatible expression 
data from both healthy and diseased tissues. Which genes change their 
expression levels in all epithelial malignancies when compared to all healthy 
epithelial tissues, can only be answered with an integrated data resource. The 
list of possible questions that can be answered is only limited by the amount of 
data accurately integrated. Thus, integration and synthesis of transcriptomics 
data is highly important for both the scientific understanding of cellular level 
phenomena as well as to support novel biomedical therapeutics and 
applications to heal diseases and manipulate biological organisms. 
 
With the four studies presented here, we demonstrate one of the largest 
efforts to build a transcriptomic reference database and show its utilization to 
both studies of genes in health and disease as well as to interpret new gene 
expression profiles in the context of the reference database. In the first two 
studies we explain in detail how the database was constructed and validated, 
with a major advance achieved in solving the incompatibility between various 
Affymetrix array generations. In the third study, we systematically defined the 
expression level map of human kinase genes across major portion of healthy 
and diseased human tissues. We were also able to characterize functional 
associations of the kinase genes through the analysis of their genome-wide co-
expression networks. The essential observation from this study was that 
kinase genes are indeed under unique transcriptional regulation so that 
accurate groups of pathological tissues (e.g. adenocarcinomas versus 
squamous) can be determined solely based on binarized kinase gene 
transcriptional profiles where the genes were divided into transcriptionally 
active and deactive states. 
 
In the fourth study, we showed how large integrated reference database could 
be used to interpret expression profiles from individual new samples. One of 
the key advances of the study was a method enabling one to quantify 
similarity of individual expression profile against a reference database at the 
level of individual genes. This method has interesting applications, like the 
ability to interpret and compare expression profiles of patients against “peers” 
or the ability to identify and quantify changes in transcriptomic programs of 
differentiating cells. 
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5. Review of the literature 
5.1. Transcriptome 
 
The central theorem in classical biology is “DNA makes RNA makes protein”. 
Thus a cell transcribes various RNA molecules by using DNA as a template to 
be used as templates in translation. At any given time point, the collection of 
RNA molecules of a cell constitutes a transcriptome of a cell. 
 
Methods and experiments aimed at measuring the expression values of single 
genes in dedicated experimental setups trace almost back to the origin of 
molecular biology. The limitations of the available methodologies forced these 
experiments to be focused on specific questions and the results were usually 
interpreted only in the context of certain cell lines, tissues or diseases. 
However, as early as 1999 Velculescu et al. [21] reported a study of the human 
transcriptomes of 19 normal and diseased human tissues by using serial 
analysis of gene expression (SAGE). Then in 2000, Warrington et al. [22] 
studied 11 different adult and fetal human tissues with high-density 
microarrays of that time to find out genes involved in cellular maintenance. 
They identified 535 genes from the studied 7000 genes as having a stable 
expression since it turns on during the fetal development. Additionally, they 
established average expression levels for genes in normal individuals and 
identified tissue specific genes for the 11 tissues. Later on Hsiao et al. [23] 
found 451 maintenance genes from 7000 studied genes to have a relatively 
stable expression across 19 distinct tissues while Eisenberg et al. [24] 
identified 575 maintenance genes from 7500 studied genes across 47 tissues. 
In 2002 Su et al. [25] studied 25 human and 45 mouse tissues, with a later 
study by Su et al. [26] containing 79 human and 61 mouse tissues. Also in 
2005, Shyamsundar et al. [27] conducted a similar kind of study of gene 
expression in healthy human tissues reporting similarity in gene expression 
patterns between anatomically or functionally related tissues. Even though 
many of the early studies searched for the elusive maintenance, also known as 
housekeeping genes, they still represent the first attempts to characterize and 
understand human transcriptomes in a genome wide scale. In other words 
they were constructing first references against which other transcriptomic 
phenomena could be interpreted. 
 
It was for long assumed that most transcribed RNAs are protein-coding, most 
likely directing the early development of methodologies towards enabling 
high-content analysis of these RNAs. Already in 2002 Kapranov et al. [28] 
found out that an order of magnitude more genomic sequence was transcribed 
than was accounted for by known or predicted exons. Practically all widely 
used microarray technologies still focus on polyadenylated RNA, which 
comprises only about 2% of the transcribed RNA molecules as described by 
Frith et al. [29]. The study of non-coding RNAs have been found to be a 
fruitful avenue as several studies revealed that non-coding miRNAs, cloned 
from Caenorhabditis elegans by Lee et al. as early as 1993 [30], were 
evolutionary widespread [31, 32] and have since shown to possess a wide 
variety of important regulatory functions [33]. These non-coding and non-
polyadenylated RNAs were found to be an important transcriptomic 
regulatory mechanism [34] and within few years there were increasing 
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collection of registries, databases and tools for research around non-coding 
RNA molecules as described by Ambros et al. and Griffiths-Jones et al. [35-
38]. The most recent research has revealed that the protein-coding part of the 
transcriptome is only a small portion of an otherwise extremely complex 
collection of various non-coding transcripts as revealed in studies by Frith et 
al., Gingeras et al. and Kapranov et al. [29, 39, 40]. Strikingly, the ratio 
between non-coding and coding RNA molecules in a human transcriptome is 
27:1, when excluding repetitive portion of the genome. According to Frith et 
al. [29] the ratio seems to increase with increasing complexity of an organism 
(1.1:1 in nematode, 2.2:1 in fruit fly and 28:1 in mouse). Actually, the entire 
concept of a gene is somewhat obsolete as the transcribed sequences are 
intertwined, nested and spliced in a complicated manner. During the past ten 
years this hidden part of the transcriptome has been brought to light, but the 
functions of those myriad transcripts remain rather unclear. What is clear, 
however, is that the complete transcriptome should be understood in much 
more complex terms with a very large number of distinct species of RNA 
molecules interacting in a highly complex manner to regulate the 
transcription and translation of protein-coding RNA species. Next-generation 
sequencing technology is rapidly combining these various research avenues as 
it allows an even more comprehensive analysis of transcribed RNA species as 
described by a series of recent studies by Metzker et al., Mortazavi et al., Pan 
et al. and Sultan et al. [41-45]. 
5.2. Gene expression analysis methods 
There are numerous methods to measure the expression levels of one or more 
genes. The most well known methods are in situ hybridization, Northern blot 
and reverse transcription-polymerase chain reaction (RT-PCR). These are 
found to be robust and reliable, but they are somewhat limited in the number 
of genes (or samples) they can effectively measure simultaneously. However, 
early on there was a recognized need to measure the entire transcriptome at 
once, thus multiple methods were developed for that purpose. Expressed 
sequence tags (EST) were perhaps one of the earliest methods allowing 
genome wide analysis of gene expression. Later developed differential display, 
serial analysis of gene expression (SAGE), dot plots and nylon filter arrays and 
microarrays allowed more comprehensive genome wide expression 
measurements. The more recently developed RNA-Seq [41-45] allows perhaps 
the first true genome wide analysis of transcribed RNA-molecules. RNA-Seq is 
based on hugely parallel sequencing capacity allowing direct sequencing of 
RNA molecules from the sample. From these sequence reads one can then 
computationally form an estimate of expression levels of transcripts, their 
sequence variation and larger genomic rearrangements like fusion genes. 
Additionally, as the technology is not based on a prior assumption of 
transcript sequences it can also identify novel transcripts. 
 
Microarray technology is currently the most established of these genome wide 
methods and is used widely in various research setups. Microarrays can be 
constructed with several methods like spotting (printing) cDNA sequences to 
glass slides with a robotic arrayer [46], by inkjet printer technology enabling 
noncontact printing by using electrical pulse to expel liquid to the glass slide 
[47] or by in situ synthesis [48, 49]. Most successful array manufacturers, like 
Affymetrix [7, 50] and Agilent Technologies [47] use in situ synthesis even 
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though the latter has also relied heavily on inkjet technology printing 
nucleotide by nucleotide to the glass slides (in situ printing). Illumina [51] has 
a somewhat differing concept where instead of using fixed positions for spots 
having oligonucleotide probes with specific sequences Illumina BeadArray 
technology synthesizes oligonucleotide probes on 3 µm silica beads which 
then self assemble in microwells. Affymetrix is by far the oldest and largest of 
the microarray manufacturers. This is also reflected in the amount of 
submitted microarray data in public repositories. For example, as of Dec 19, 
2010, Gene Expression Omnibus (GEO) contained 90 827 Affymetrix based 
gene expression samples in comparison of 14 674 samples measured with 
Illumina and 4930 samples measured with Agilent Technologies. Next 
generation sequencing is rapidly replacing microarrays in almost all 
applications. However, the current availability of next generation sequencing 
data is nowhere near the amount of microarray data generated by the 
scientific community over the years. 
 
In situ synthesis used by Affymetrix is based on light-directed synthesis of 
oligonucleotide probes on a silica substrate [49, 52]. The probes are built 
nucleotide by nucleotide by applying light on selected probes while the 
synthesis chemistry takes place only in the presence of light. A special mask is 
used to provide the exact configuration of light for each cycle of synthesis. 
Cycles are repeated until the desired probes are constructed. 
 
There are two distinct types of gene expression microarrays in terms of 
sample hybridization protocol: single-channel and dual-channel arrays. The 
fundamental difference is that in dual-channel arrays two samples are 
differently labeled and hybridized onto a single array. The results are 
interpreted in terms of ratio between the different labels and thus reveal 
relative expression levels between the samples. In single-channel arrays only 
one labeled sample is hybridized to each array and therefore the results are 
interpreted more in a manner of absolute expression values than relative 
expression values. However, the requirement for the normalization of 
expression values results in non-absolute values even in the single-channel 
arrays. With single-channel arrays comparisons between the samples are done 
computationally. Two-channel arrays are somewhat outdated and most 
studies nowadays are done with single-channel arrays. 
 
Affymetrix arrays are single channel arrays, consisting of 25 nucleotide long 
perfect match probes (PM) and mismatch probes (MM), together forming 
probe pairs. The perfect match probe is complementary to a desired position 
of specific RNA sequence while the mismatch probe is otherwise the same 
except the middle nucleotide is changed to complementary one. Ten to twenty 
of these probe pairs form a probeset. There are 6076 - 38191 probesets, 
depending on the array generation. About 80% of the probesets detect the 
antisense strand (mRNA) of the desired gene (these are denominated by “_at” 
at the end of the probeset ID according to Affymetrix probeset naming 
convention), about 10% cross-hybridize to same gene family (denominated by 
“_a_at”), about 5% cross-hybridize to some other gene (denominated by 
“__s_at”) and about 5% contain at least one probe that hybridizes with some 
other sequence (denominated by “_x_at”). This setup of probes, probe pairs 
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and probesets has been subject to comprehensive review and improvement by 
the bioinformatic community as reviewed later on. 
 
As Affymetrix arrays are single-channel only, one biotin-labeled RNA sample 
is hybridized on the array. The array is then stained with phycoerythrin-
conjugated streptavidin, and after washing it is scanned with a Gene Array 
Scanner (manufactured by Affymetrix). The scanner provides the intensity 
values of each probe pair to be further processed by various algorithms. 
 
There has been a lot of discussion about the quantitative accuracy of 
microarrays but Canales et al. [53] have shown that there is a good correlation 
between quantitative methods like RT-PCR and microarrays. Recently, 
comparison between Affymetrix arrays and RNA-Seq has also shown rather 
high correlations. Marioni et al. [54] showed that information in single lane of 
Illumina sequencing appears to be almost equivalent with single Affymetrix 
array in detecting differentially expressed genes. However, sequencing 
technology allows more sensitive detection of low expressed transcripts, 
alternative splicing and also is able to identify novel transcripts. 
 
It has been known already for some time that fundamental limitations of 
microarray sensitivity exist especially in detecting low expression levels [55]. 
Similarly, according to Canales et al. [53] largest differences between the 
quantitative methods and microarrays are due to the lower sensitivity of 
microarrays at the low expression levels and due to the differing probe 
sequences. Also Hwang et al. [56], Nimgaonkar et al. [57] and by Autio et al. 
[58] revealed that differing probe sequences are a major source of noise when 
comparing expression level measurements from different technologies. 
 
Through several studies, like the influential Microarray Quality Consortium 
(MAQC) [5, 6, 59], microarrays have been established as a robust and reliable 
technology to measure genome wide expression profiles. Especially Affymetrix 
arrays were found to have high reproducibility between laboratories [5] as 
well as to be reproducible between replicates according to Nimgaonkar et al. 
[57]. Barnes et al. and Jarvinen et al. [60, 61] report that there is considerable 
overall concordance between different microarray platforms. Recently 
microarray data has also shown to be in theory reliable enough for clinical use 
by the extension of the MAGC study (MAGC-II) [59]. However, the 
experimental setup and data-analysis quality of many studies leaves room for 
improvement before microarray-based classifiers can be used routinely in 
clinical practise. Nevertheless, some microarray-based tests, like MammaPrint 
[62], are already in clinical use. 
 
5.3. Data processing and normalization of Affymetrix 
microarray data 
Data produced by microarray scanners is considered to be raw data, as it 
requires substantial preprocessing and normalization before actual biological 
data analysis can be performed. Fundamental steps of preprocessing and 
normalization should contain at least a way to link the intensity of each 
measured probe (or probepair in the case of Affymetrix) to a preferentially 
Review of the literature 
 
11 
distinct biological feature like gene, transcript or exon. There should also be a 
way to deal with absurd intensity values likely resulting from technical 
artifacts as well as to compensate for variance in overall hybridization 
efficiency. The Affymetrix Microarray Suite version 5 (MAS5) [63] provides a 
suite of algorithms to perform the necessary preprocessing and normalization 
for Affymetrix arrays. 
 
The scientific community has developed multiple additional data processing 
and normalization methods for Affymetrix arrays. In the same year as 
Affymetrix published MAS5, Li and Wong published the model-based 
expression index, dChip, providing another way to combine probe level 
intensity values into the final expression value of a probeset [64]. This was 
followed in 2003 by the highly influential Robust Multichip Average (RMA) by 
Irizarry et al. [65]. Several other methods like ChipMan, gMOS, GCRMA, 
PLIER, RSVD, UMTrMn, VSN, ZAM and ZL are expertly reviewed by Irizarry 
et al. [66]. Affymetrix arrays contain probes in pairwise manner, for each 
Perfect match probe designed to measure the transcript of interest the array 
contains also Mismatch probe. This latter probe is otherwise equal to Perfect 
match probe except that the middle nucleotide of the 25-mer is changed. 
Methods developed by the scientific community generally vary in how Perfect 
match and Mismatch probes are handled in the calculation of summary 
expression value and in the type of background correction made. However, 
irrespective of comprehensive studies of various preprosessing methods, like 
performed by Irizarry et al [66], there is no definite optimal preprocessing 
method for all purposes. 
 
Affymetrix provides CDF-files containing array layout information, namely 
description of physical locations of the oligonucleotide probes on the array as 
well as information to which probeset each individual probe belongs to. In 
addition, Affymetrix provides information on which gene each probeset 
measures. This probeset to gene linking information can also be obtained 
from major genome browsers like Ensembl [67], UCSC genome browser [68] 
and NCBI genome browser [69]. However, Dai et al. [70] have shown that 
remapping of the probe sequences to the newer genome builds can 
significantly improve the data quality. Instead of relying on old definitions of 
which probe belongs to which probeset, Dai et al. [70] map individual probes 
to genes thus completely skipping the probeset level. 
 
The need for normalization arises largely from the need to analyze multiple 
arrays together. In general, when one compares two or more arrays together 
one sees considerable variation in signal values. This variation can be broadly 
divided into biological one and technical one. Biological variation arises from 
the varying expression levels between the samples and it is usually the 
information that the researcher is seeking for. On the other hand, technical 
variation is, for example, caused by differences in sample handling, sample 
preparation or in the production of arrays or in the settings of the scanner. By 
far the largest challenge of the entire microarray field is to separate these two 
variations from each other and reliably eliminate technical variation. 
Affymetrix recommends a normalization where the total intensity of all 
probesets is scaled to be the same user-defined value across multiple arrays 
being compared together, but this simple approach does not perform well if 
Review of the literature 
 
12 
there are non-linear relationships between the arrays and practically not at all 
if there is a need for gene-specific normalization. This limitation arises from 
the fact that the scaling factor simply applies equal correction to all values 
within the array, thus it is unable to account for a need of any gene or value 
specific correction. RMA performs the widely applied quantile normalization, 
which replaces the maximum value of each array with the mean of maximum 
values; second largest value is replaced by the mean of the second largest 
values etc. This will give each array same distribution of values and is 
generally thought to be a relatively robust and efficient normalization. 
However, the approach has some challenges if all arrays do not have same set 
of genes and in the case of very large datasets there might be some 
computational challenges. 
 
Normalizations generally applied to Affymetrix arrays, like scaling or quantile 
normalization, are suitable for reducing technical variation between arrays of 
the same generation. However, as Hwang et al. [56], Elo et al. [71], Canales et 
al. [53], Nimgaonkar et al. [57], Mecham et al. [72], Autio et al. [58] and 
many others have shown, one of the largest sources of noise in expression 
measurements originates from using nucleotide probes with varying 
sequences. This severely prohibits comparing or integrating data from 
multiple array generations. Hwang et al. [56] and Elo et al. [71] described 
methods how to improve comparability of Affymetrix array generations by 
selecting only a subset of probes. While this leads to a significant 
improvement in comparability it also greatly reduces the amount of usable 
data, as there is only a limited amount of overlapping sequences between the 
probes of two array generations. This is due to the logic of designing in situ 
synthesized oligonucleotide arrays, which leads to a complete redesign of 
probe sequences with new array generations with improved gene content. 
Other known approaches to perform cross-platform comparison include co-
inertia analysis by Culhane et al. [73]. 
5.4. Sources of publicly available gene expression data 
As the application of microarrays became widespread among the scientific 
community, the need for systematical storage of microarray results associated 
with publications increased in importance. To address this need, large 
bioinformatic projects were launched which resulted in construction of public 
expression data warehouses like Gene Expression Omnibus (GEO) [14], 
ArrayExpress [74] and Stanford Microarray Database (SMD) [15]. The 
primary aim of these warehouses was to enable systematic and long-term 
storage of large expression datasets and to allow retrieval of these datasets by 
the wide scientific community. For the sake of scientific credibility of these 
increasingly larger and more complex study setups, there was a need to 
describe the experiments in great detail. Brazma et al. [75] responded to this 
need and in 2001 published a standard known as minimum information about 
a microarray experiment (MIAME). Later array warehouses have mostly 
implemented this guideline and to some extent the details of the experimental 
setups of array studies have started to be more systematically described. In 
addition to these public gene expression data warehouses there is a large 
amount of gene expression data available at the websites of institutes, 
laboratories and research groups. 
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However, irrespective of the more strict guidelines and standards for 
publications, the actual repeatability of microarray-based studies is very low. 
This was demonstrated in a striking study by Ioannidis et al. where they 
showed that the data analysis of 10 out of 18 microarray based studies could 
not be reproduced based on their original publications [76]. The raw data 
itself produced by the modern microarray platforms is generally repeatable 
and reliable, but most publications relying on microarray-based data do not 
give adequate description of the used data analysis methods and their 
parameters nor do they release all data. This severely hinders real use of the 
results beyond the single publication. In many cases the only way for the 
scientific community to take advantage of and compare the results to other 
studies is to start with raw data and do the entire analysis again. However, this 
approach, when applied to multiple datasets, leads easily to the need for more 
and more complex microarray data meta-analysis methods and resources. 
5.5. Meta-analyses of gene expression data 
While public expression data warehouses like GEO [14], ArrayExpress [74] 
and SMD [15] served the main purpose of storing published data in a 
systematical manner, they did not originally support any analysis of the stored 
data. However, already 2003 Huminiecki et al. [77] showed that knowledge 
mining from large public databases of gene expression information can 
provide novel insights. One of their main results was that expression profiles 
extracted from variety of different sources of expression data (like Gene 
Expression Atlas [25], SAGEmap [78] and TissueInfo [79]) have relatively 
good correlations. 
 
Once the meta-analysis of multiple datasets was shown to be a fruitful 
research direction by multiple authors [17, 77, 80-84], several gene expression 
databases and resources started to appear, with Oncomine [19], CELSIUS 
[16], Genevestigator [85] and BioGPS [86] being the most notable. These 
approaches have proven to be enormously useful as everyday genomics 
research tools. However, the biological heterogeneity inherent in all samples 
from biological organisms sets high requirements for the annotation of data in 
these reference databases. At present, computational text mining is not 
accurate enough to be able to handle biological complexity of the annotation 
even with the microarray experiment standardization efforts like MIAME [75]. 
Likewise, the data-driven computational approaches adopted by CELSIUS 
[16], where some of the biological characteristics of new samples are derived 
from the clustering of the samples among existing samples, is not able to 
handle the full biological complexity of sample annotation. 
 
In addition to the biological challenges of the annotation, the mathematical 
challenges of data comparability also affect how meta-analysis studies are 
done. As demonstrated by Hwang et al. [56], Elo et al. [71], Autio et al. [58] 
there is a lot of technical variation between even the array generations of a 
single manufacturer (like Affymetrix Inc.), due to the different probe 
sequences. Previous correction methodology suggested by the same authors 
leads to the exclusion of incompatible probes and while it greatly improves the 
data comparability it also greatly reduces the amount of data. One might 
assume it to be the main reason why none of the large array meta-analysis 
studies have adopted those correction methods. 




One of the largest and most influential meta-analysis projects done by the 
group of Arul Chinnayan, Oncomine [19], chose to represent its data study by 
study, thereby circumventing the comparability issue at the expense of data 
integration. In their original publication [19], they showed one of the first 
gene centric analyses by visualizing receptor tyrosine-protein kinase erbB-2 
(ERBB2) gene expression levels across multiple tissue and then across 
multiple samples of healthy and ductal carcinoma of breast. This combined 
data from multiple datasets and allowed one to draw conclusions about the 
expression level activity of the ERBB2 across various tissues. Also based on 
the hypothesis that therapeutic agents are most effective in cancers in which 
their targets are highly expressed they conducted a test of drug repositioning. 
By using Therapeutic Target Database (TTD) [87] and PubMed they identified 
148 drugs and their targets. Then they proceeded to test in which cancers the 
target of the drug is statistically significantly overexpressed when compared to 
corresponding healthy tissue and discovered numerous interesting 
observations. They also published more advanced studies where they were 
able to show how genes with binding sites for typical cancer associated 
transcription factor like E2F were generally overexpressed in a variety of 
cancers whereas genes with a binding site for some other transcription factors 
like Myc-Max and C-Rel were overexpressed in specific types of cancers as 
described by Rhodes et al. [18]. This kind of analysis is an illustrative example 
of how gene expression meta-analysis can be used to uncover pathways 
related to the progression of cancer, a large mass of data leads to more reliable 
data analysis and allows more widely applicable conclusions to be drawn. The 
data integration approach chosen by Oncomine, while relatively simple 
approach to implement, leads to further challenges in development of data 
mining methods able to deal with fragmented datasets. Also visualizing 
various transcriptomic phenomena is challenging with fragmented datasets 
and therefore for a single question there might be multiple answers. 
 
CELSIUS [16], Genevestigator [85] and many other projects have adopted 
practically the same approach. Higher numerical comparability has only been 
achieved in meta-analysis studies, like Greco et al., Lee et al., Segal et al. and 
Xu et al. [17, 80-83, 88], focusing on particular biological questions but not 
aiming to build integrated multiuse resource of transcriptomic data. On the 
commercial side GeneLogic Inc. aimed at building a comprehensive reference 
database and resolved the comparability issue by analyzing all relevant 
samples with a single array Affymetrix generation [89]. While this is 
undoubtedly the best approach, it is an economically completely unfeasible 
option in academic setting due to the constantly changing microarray 
platforms. 
 
5.6. Gene expression – step between sequence and function 
A gene’s expression level provides intriguing information. Sequence level 
variation, or any causative link to the function of the protein encoded by the 
gene are hard or near impossible to derive from the gene expression data. The 
relation between gene expression and actual level of active protein is also hard 
or impossible to accurately derive from gene expression data. Nevertheless, it 
is one of the most important pieces of information, as the transcription of a 
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DNA sequence to mRNA is needed for translation and ultimately for the 
production of proteins, the functional components of cells. Therefore, since 
the sequencing of the human genome revealed a systematic catalogue of 
human genes, understanding the expression levels and ultimately functions of 
genes has become an ever more challenging and important task. The first step 
in understanding how the sequence transforms into function is to identify in 
which tissues genes are expressed. As previously described, there have been 
numerous studies establishing expression level information for an increasing 
gene and tissue content. As the expression levels of genes do not correlate in 
straightforward manner with the levels of proteins there should be separate 
analyses establishing both protein level and activity information. There are 
also highly succesfull studies establishing protein level information for 
majority of genes in considerably wide collection of tissues, such as the human 
protein atlas described by Uhlen et al. [90]. Newer technological advances 
allow higher content proteomics assays, such as lysate arrays [91], revealing 
protein levels across various healthy and diseased tissues in a single assay. 
 
Cancer, a malignant neoplastic growth of a tissue, is a disease driven by 
various genetic changes and defects. Therefore the study of cancer-associated 
alterations, either at the level of DNA sequence changes, or at the level of gene 
expression is an important part of cancer research. Even though various 
sequence level changes of the non-transcribed parts of the genome might be 
indicative of or even causative for the disease, a key step in the understanding 
of the development of cancer is the analysis of the amounts of transcribed 
sequences and their exact sequence composition. 
 
In the progression of cancer, one of the most studied families of genes is 
kinases. By phosphorylating various substrates kinases conduct and/or 
amplify signal transduction throughout the cell and therefore play an essential 
role in the signalling circuits of cells. Thus, for cancer cells, which reprogram 
various signalling circuits to enable their uncontrolled cell division and 
growth, kinase genes are especially critical. Indeed, among the known human 
cancer genes the most commonly represented protein domain is the protein 
kinase domain [92], indicating the essential role of kinases in the malignant 
progression. The most common cancer related genetic change targeting a 
kinase gene is an activating somatic mutation [92], but germ line mutations, 
recessive mutations, inactivating mutations, gene fusions, amplifications and 
deletions are also known. Some of these have an effect on the expression level 
of the kinase gene, like the amplification of ERBB2 gene in ductal breast 
cancer leading to an overexpression of the transcript and subsequently to a 
larger amount of the corresponding tyrosine-kinase receptor at the surface of 
the cell [93, 94]. While kinase genes are among the most important genes to 
understand in the development of cancer, they are also very challenging to 
study for the reasons explained below. 
 
For each kinase, it would be important to know i) what specific kinds of kinase 
gene sequences are transcribed ii) at what level they are transcribed iii) at 
what level the kinase proteins are present and iv) whether the kinase proteins 
are enzymatically active, and v) what is the actual biological function of the 
kinases. Even though there are some successful studies finding expression 
level signature indicative of the specific mutations [95, 96], direct sequence 
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analyses are needed to truly understand what is being transcribed. Next-
generation RNA sequencing technology [41-45], allowing both efficient 
sequence analysis and expression level analysis from the same sample, is 
currently a promising way for the functional genetics advances. 
 
Kinases have been the subject of various studies reporting sequence level 
changes in malignancies. Overall protein sequence similarity has been used to 
construct a sequence based classification of kinases [97, 98], comprehensive 
resources for studying kinase activity in various signalling pathways have been 
constructed [99] and various methods for defining the phosphorylation status 
of kinase substrates have been developed [100]. Nevertheless, due to the 
technical limitations kinase protein levels and enzymatic activity are 
practically impossible to measure across the entire kinome in all relevant 
tissues. Systematic expression level analysis focusing on kinase genes has 
been largely lacking, partly perhaps because of the difficulty of obtaining data 
for it and partly because kinases are mainly thought to function at the protein 
level without significant regulation at the transcriptome level. 
 
Gene and ultimately protein sequence can be used to make inferences as to 
the function of the protein, like in the case of kinase genes the domain 
responsible for the kinase activity can be recognised from the sequence. 
Mutations in a specific nucleotide of the gene can be predicted to have effect 
on the function of the protein. However, this kind of analysis cannot always 
reveal higher-level biological processes in which the protein participates nor 
are the protein domains always conserved enough to be recognised. Genome-
wide gene expression measurements not only provide the possibility to 
characterise which genes are expressed in which tissues, but also provide 
tentative information as to which biological functions the gene products might 
participate in. Merely finding a group of genes differentially expressed in a 
group of tissues or cells subject to a specific perturbation might indicate that 
corresponding genes are participating in certain function responding to the 
perturbation. Taking this simple assumption somewhat further leads one to 
the co-expression analysis where correlating expression levels between genes 
provide an indication of similar functions as previously studied by Lee et al., 
Prifti et al. and Zhang et al. [17, 101, 102]. This is especially true in the case of 
protein complexes as the complex is rarely functional if all of its components 
are not present. It has been shown that if some of the co-expressing genes 
have known functions then under certain assumptions these functions can be 
assumed for unknown genes. These methods have been expertly reviewed by 
Hu et al. [103]. Segal et al. and Xu et al. [80-83] took the study of gene 
function even further by demonstrating how one can identify networks of 
interacting modules of coregulated genes. Methods used in these studies vary 
somewhat, but the core idea is the same. Having a large collection of 
integrated expression data makes it possible to uncover functional 
associations of genes through careful analysis of their co-expression 
environment. 
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5.7. Interpreting microarray data in the context of existing 
data 
On the field of nucleotide and amino acid sequence analysis tools, like BLAST 
and BLAT [104, 105], enabling comparison of an unknown sequence to a 
reference database of known sequences has proven to be essential. Similarly 
on the side of gene expression data analysis interpreting new data in the 
context of existing data has been found to be a useful approach. One of the 
earliest to demonstrate this was Parmigiani et al. [106] in 2002 who 
constructed a statistical framework allowing probabilistic assignment of 
tumors to molecular profiles. This has been followed by many others like 
Zilliox et al. [107] with their gene expression barcode methodology predicting 
tissue type of individual sample with the help of gene expression barcodes 
constructed from a reference data. Lamb et al. [108] constructed Connectivity 
Map, showing how different drugs change the expression profile of various 
cell lines and enabled comparison of gene expression changes observed in 
one’s own studies to the established expression changes caused by drugs. 
Caldas et al. [109] demonstrated a methodology to retrieve experiments 
resembling the one’s own experiment based on the measured expression 
values. More recently Lopez et al. published [110] TranscriptomeBrowser, a 
resource allowing search of transcriptomic signatures from a large collection 
of microarray experiments. 
 
The defining aspect of all of these is that similar experiments are not 
identified based on the similar annotation but based on similar data values. 
Therefore these can be seen as analogs of BLAST [105] and BLAT [104] types 
of sequence analysis tools where the sequence of an unknown sample is being 
compared with those of all other sequences available in the reference 
sequence databank (like GenBank). However, using a gene expression 
database as a reference to interpret new samples is somewhat more 
complicated than comparing a nucleotide or amino acid sequence to a 
database of sequences. Most importantly, there is no simple definition of 
similarity between expression level of a gene in the query sample and its 
expression in the reference database. 
 
Nevertheless, the ability to compare an individual expression profile against 
reference data could provide new tools for personalized medicine. The 
scientific literature describing cancer related gene expression changes and 
signatures is rapidly increasing, but very few of those findings have been 
transferred into clinical practise. Reasons are numerous, but one specific 
challenge is that gene expression measurements from the patient’s tumor 
itself are rather difficult to interpret without a proper reference. At 2006 
Gruvberger-Saal et al. [111] expertly reviewed many of the challenges of using 
microarrays in clinical settings. They especially pointed out a need for 
standardization of the methods, arrays and easier comparability between the 
studies. It still remains to be seen how established microarray based 
diagnostics tests, like MammaPrint or TargetPrint [112], perform outside the 
patient population used to develop those tests. Quite often microarray based 
classifiers are validated with a limited population of samples, perhaps some 
specific ethnic group or disease subtype. Therefore it is obvious that more 
standardized reference data is needed in large quantities as well as methods to 
robustly compare patients to it. 
Aims of the study 
 
18 
6. Aims of the study 
 
The aims of the study were to 
 
• Collect a significant amount of published human gene expression data 
into a unified database and apply a systematic annotation to the 
samples. 
• Develop methods to overcome mathematical and biological challenges 
in data integration across different microarray platforms. 
• Develop methods to mine the integrated data both in a gene wise and 
sample wise manner in order to acquire new biological and biomedical 
knowledge. 
• Develop methods and statistical tools to compare molecular profiling 
data from one sample against a comprehensive collection of annotated 
reference data. 
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7. Materials & Methods 
 
Each publication (I-IV) describes in detail all the materials and methods used 
in it. However, the main methods are briefly previewed here for completeness 
and convenience for the reader. 
 
7.1. Data acquisition and archiving 
Data used in publication I was collected in the form of Affymetrix CEL files 
(containing intensity data as measured by the microarray scanner) mainly 
from public sources like GEO and ArrayExpress. Some additional studies were 
obtained directly from authors of substantial gene expression experiments. As 
any collection of CEL files might theoretically contain duplicate files the 
uniqueness of each CEL file was tested by using the cyclic redundancy check 
algorithm (cksum) [113]. Cksum provides “fingerprint” of the content of the 
file, usually used to check integrity of files, but it can be adapted for this 
purpose as well. This step significantly reduced the risk of including the same 
sample twice in the data collection. Data was archived in a Linux-system with 
additional Perl scripts to maintain the archive integrity and calculate the 
cksums. 
 
7.2. Data integration 
7.2.1. Data preprocessing 
All CEL-files were preprocessed with the Microarray Suite 5.0 (MAS5) 
algorithm, implemented with C++ by using libraries provided by Affymetrix 
Inc. MAS5 produces both quantitative expression values as well as qualitative 
values from the raw data file (CEL-file). MAS5 performs a background 
correction by calculating and subtracting the weighted sum of the background 
signal of the various zones of the array from the values of the individual spots. 
A detection call, a qualitative value, indicates whether the transcript is reliably 
detected (Present) or not detected (Absent) by the probes of the array. 
However, the normalization schema used in this study does not use detection 
calls. 
 
The quantitative expression value is calculated by One-step Tukey’s Biweight 
Estimate to represent the level of expression of the corresponding transcript. 
First the signal of each probe pair is estimated with the log of Perfect match 
probe intensities after a subtracting stray signal estimate. The stray signal 
estimate is formed according to three rules as described in the Affymetrix 
statistical reference guide [63] 
i) if the Mismatch probe intensity value is less than the Perfect match 
probe value, the mismatch intensity is considered to be informative 
and a proper estimate of the stray signal, 
ii) if the Mismatch probes are generally informative across the 
probeset except for a few probes, the stray signal is calculated as the 
bi-weight mean of the Perfect match and Mismatch ratio, 
iii) if the Mismatch probes are generally uninformative, the stray signal 
is defined to be slightly less than Perfect match signal. 
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The closer the signal of the probe pair is to the median of all probe pairs of the 
corresponding probeset the stronger the weight that probe pair gets. These 
weights are then used in the weighted mean of all probe pair signal values to 
determine the final signal value. 
 
To avoid the somewhat obsolete probeset to gene mapping provided by 
Affymetrix Inc. we used alternative CDF files mapping individual probes 
directly to the Ensembl gene IDs. This is described in more detail both in 
section 5.3 and in publication I. 
7.2.2. Samplewise normalization 
Equalization transformation was used to normalize each sample preprocessed 
with MAS5. Mean 8 and standard deviation 2 were selected as parameters for 
desired distribution based on the comparison to median (7.92) and standard 
deviation (2.3) of all 9783 samples. Equalization transformation is described 
in more detail in publications I and II as well as by Hautaniemi et al. [114]. 
7.2.3. Genewise normalization 
Array-generation-based gene centering (AGC) was performed to alleviate 
noise from varying probe sequences between array generations. In AGC each 
gene is corrected for array-generation-based bias of measuring the expression. 
This is based on the assumption that having a large enough collection of 
samples analyzed the distribution of values of a gene contains all possible 
expression values across all tissues for each array generation. Thus the 
difference between the distributions of the gene between array generations is 
largely due to the technical variation caused by varying probe sequences. AGC 
is described in more detail in publications I and II. 
7.3. Data annotation 
7.3.1. Sample and gene annotation 
Annotation provided by the original authors was retrieved with Perl scripts 
(for GEO and ArrayExpress data) or manually from publications and their 
supplementary tables. The annotation provided information about the 
biological nature of the sample. A team of biologists and medical doctors then 
manually curated annotation of each sample resulting in 17 fields of 
information relevant to samples biological characteristics. The information 
includes for example anatomical system from which the sample originates, 
pathological status, sex and age. These fields are listed in Table 1. This 
annotation was regarded as primary annotation. 
 
A secondary annotation layer was then constructed by defining groups of 
samples having certain combinations of primary annotation values. This 
allowed easy implementation of different levels of annotation, like sample 
group “breast cancers” and separate sample groups of histological subtypes of 
breast cancer. 
 
As the gene definition in GeneSapiens is based on Ensembl genes the 
annotation for each gene was fetched from Ensembl by using custom written 
Perl scripts. 
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7.4. Data validation 
7.4.1. Multidimensional scaling 
In publication I classical multidimensional scaling [115] was used to visualize 
distances between thousands of gene expression profiles to understand what 
kind of clusters they form. Manhattan distance, also known as taxicab 
distance, was used as distance metric (see Equation 1 for Manhattan distance 




d((x1,y1),(x2,y2)) =| x1 − x2 | + | y1 − y2 | 
 
Calculation of the Manhattan distance between all pairs of samples results in a 
symmetrical distance matrix of thousands of rows and columns. 
Multidimensional scaling (MDS) was used to reduce the number of 
dimensions of the matrix and to represent the distances between samples in a 
selected number of dimensions. In publication I, three-dimensional projection 
was used whereas in Figure 6 two-dimensional projection was used. 
Additionally, in Figure 6 Pearson correlation coefficient was used as the 
distance metric. In MDS figures the distance between dots, each representing 
an individual sample, approximate the true (Manhattan or Pearson 
correlation) distance between the expression profiles. 
7.4.2. K-means clustering and rand index 
In publication I k-means clustering was used to test the goodness of the 
normalization. K-means clustering can be used to partition gene expression 
samples into k clusters. K-means clustering assigns each sample to a cluster 
whose mean expression profile is most similar to the sample. Clustering was 
performed with default parameters in R and allowed to run a maximum of 
100,000 iterations and the initial centres of the clusters were given as median 
profiles of either array generations or tissues. The aim was to test whether 
samples form clusters based on their array generation type or rather based on 
their tissue type. The results of k-means clustering was tested with corrected 
rand index [116] by using the flexible procedures for clustering (fpc) library in 
R. The corrected rand index can be used to quantify how randomly class labels 
are assigned into different clusters. The corrected rand index varies between 0 
and 1. A 0 means that class labels are randomly segregated among the clusters 
and 1 means non-random segregation (like all occurrences of one class are in 
single cluster). 
 
7.4.3. Kullback-Leibler divergence of housekeeping genes 
Housekeeping gene expression stability was one measure of the goodness of 
normalization used in the publication II. It was assumed that expression 
values of each housekeeping gene are distributed similarly across all the array 
generations. To measure the differences in distributions we used the 
Kullback-Leibler divergence (KL-divergence) [117, 118]. This measure of 
divergence can be used to quantify how much two distributions differ. The 
range of expression values of each housekeeping gene was divided into 50 bins 
so that each bin contains 2% of the expression values. Then the distribution of 
expression values of housekeeping genes across all array generations was 
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compared with KL-divergence to distribution of expression values in each 
array generation. We used 126 housekeeping genes [24] in this analysis. The 
aim was to show that the KL-divergence between housekeeping gene 
expression value distributions in each array generation and the combined 
distribution across all array generations diminish after the normalization. 
This indicates that after the normalization housekeeping gene expression 
profiles are more alike irrespective of the array generation type used to 
measure them and therefore the data is biologically more sensible. 
7.5. Data analysis methods 
7.5.1. Definition of transcriptional activity 
In publication III we demonstrated a method to define the state of 
transcriptional activity of genes. The method relied on defining background 
expression level by calculating the entropy of sample annotation class labels in 
a sliding window (with width of 5% of maximum expression value of the gene 
in question) over 1603 healthy tissue samples. Background expression level 
was defined to be smaller or equal than the midpoint of the sliding window 
with highest entropy value plus two times the standard deviation below the 
midpoint. This results in 95% coverage of the assumed normal distribution of 
the background expression level of the gene. If the median expression of gene 
in a tissue was above the background expression level it was defined as 
transcriptionally active and assumed to be under active and positive 
regulation of transcription in that tissue. 
 
In the analysis of all human genes (Figure 8, Figure 9 and Figure 10) the 
method was further modified to more effectively handle genes actively 
transcribed in all tissues (i.e. housekeeping genes). The location of the sliding 
window with the highest entropy was further analyzed to identify 
housekeeping genes. If the midpoint of the sliding window was above the 
lower 35:th percentile of expression values and the sum of all entropy values 
at lower expression values than the location of the sliding window was less 
than 0.95 of the theoretical maximum entropy sum, the gene was classified as 
housekeeping gene. After this modification the method is able to classify genes 
being highly expressed in all samples as housekeeping genes. 
7.5.2. Co-expression environment biological process 
enrichments 
Correlation coefficients between all gene pairs (11 906 genes) in the genome 
were calculated over 5712 samples, and the genomic co-expression network 
was constructed by forming links between genes whose correlation coefficient 
was over the gene specific threshold. Threshold was defined to be the 99.9 
percentile of all correlations for the gene in question. This gene specific 
threshold was found to be important factor as each gene seems to have a 
different range of correlation coefficients with other genes. Then the co-
expression network around each of the kinase genes was explored by 
performing 500 random walks on the network, each 5 steps long and 
originating from the gene of interest, collecting all other genes (nodes of the 
network) encountered. Steps were not allowed to go directly backwards. As a 
result of this we acquired the frequency distribution of genes encountered in 
the near vicinity of the kinase gene. This distribution of genes was then 
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analysed in terms of the relative enrichments of biological processes as 
defined by Gene Ontology (GO-BP) by using the GOSim R library [119]. The 
method took into account both the topology of the genomic co-expression 
network as well as the dynamic range of correlation coefficients each gene has. 
7.5.3. Calculation of gene expression density estimates 
For the purpose of alignment of expression profiles to the reference data we 
calculated density estimates of the expression distribution of each gene in 
each reference tissue. Simplified schema of the density estimate formation is 
shown in the Figure 1. The estimates were calculated by using fast Fourier 
transformation based approximation of kernel density estimates with 
Gaussian window. Bandwidth selection was done as described by Scott et al. 
[120]. The density was estimated from 0 to maximum expression value in the 
entire dataset plus two times the highest bandwidth for that gene, with 512 
equally spaced points. 
 
 
Figure 1 Simplified schema of forming expression density estimates of a gene in two 
tissues. A) Individual expression measurements of a gene in two tissues. B) The range 
between 0 and maximum expression value of the gene is divided into 512 equally spaced 
points. C) One way to visualize density estimate formation is to situate normal 
distribution around each datapoint with a mean value of the value of datapoint and 
standard deviation equal to the bandwidth. D) Final density estimate can then be 
understood as a sum of normal distribution values at each evaluation point. The resulting 
diagram has an area of one and the height of the diagram at each evaluation point 
indicates the density of observations at that point. In other words, density estimate 
describe what expression levels are typical for the gene (in the tissue in question). 
7.5.4. Alignment of an external sample to gene expression 
density estimate 
Constructing gene and tissue specific density estimates of a reference database 
allows one to compare a single external expression profile to the database. 
Expression values of each gene in the external query sample are compared to 
density estimates of the gene in each reference tissue. Separately for all 
tissues, the closest evaluation point is identified and corresponding density 
value is found. The “goodness of match” of the query sample to the reference 
tissue in terms of the particular gene is the proportion of evaluation points 
having a lower density value than the gene’s value in the query sample. The 
resulting value is called the tissue match score (tm-score) and it varies 
between 0 (not “matching”) and 1 (perfect “match”). For example, if an 
expression value of the query sample for a gene situates at the evaluation 
point having the highest density in the tissue then the gene gets tm-score of 1 
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that tissue. This is repeated for expression values of all genes in the query 
sample, essentially leading to a matrix of tm-scores (tm-score for each gene in 
each reference tissue). 
 
Even though the tm-score defines how well the expression value of a gene in 
the query sample matches the expected expression values of the reference 
tissues it does not tell whether the expression value is at a level unique for the 
reference tissue. To find how uniquely expression values of the query sample 
matched each tissue we transformed tm-scores into tissue-specificity scores 
(ts-scores). The ts-score for a gene for a tissue is the mean of the ratio-
weighted differences of the tm-score for the tissue and tm-scores for all other 
tissues. The ratio weighting is done so that the larger the ratio between the 
tm-scores, the higher the resulting ts-score will be. Ts-score indicates how 
well the tm-score of a gene categorizes the query sample into a tissue. The ts-
score varies between -1 and 1. A ts-score of 1 for a gene indicates that the 
query sample had an expression value specific for the tissue in question. A ts-
score of -1 indicates that the gene has a specific expression value for the tissue 
in question but the query sample did not have that expression value. The 
mean of the ts-scores for a tissue is used as a score describing the similarity of 
the query sample to the tissue. 
7.6. Visualization methods 
7.6.1. Body-wide expression profiles of genes 
To provide a comprehensive view of gene expression over healthy and 
pathological tissues specific visualization methods were developed. In these 
body-wide expression profiles the expression level of the gene is on the y-axis. 
On the x-axis are all samples of the database ordered in terms of the 
anatomical origin of the sample as well as in terms of the pathological status 
of the sample, thus each dot represents the expression level of a gene in one 
sample. The anatomical origins of each sample are marked with colored bars 
below the plot. In the first part of the plot are healthy tissue samples, in the 
second part malignant tissues and in third samples of other diseases. Tissues 
having an expression level at least one standard deviation higher than average 
expression of all tissues of the same type (healthy, cancer, or other disease) or 
ones whose 90th percentile of expression in a tissue is equal or higher than 
2*interquartile range (IQR) + 75th percentile of the same type (healthy, 
cancer, or other disease) are additionally colored in the figure (legend at the 
top left corner of the image). These plots have been used in publications I, III 
and IV. 
 
Another frequently used plot type is boxplot. On the left side of these plots are 
healthy tissues (green) and on the right are malignant tissues (red). The 
number of samples per tissue is shown in the parentheses. The line shows the 
median expression level. The box extends to the 25 and 75 percentiles with 
whiskers extending to the most extreme data point which is no more than 
1.5*IQR from the median. Outliers beyond this are shown as individual dots. 
These plots have been used in publications I, III and IV. 
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7.6.2. Visualization of co-expression data 
In publication III the co-expression enrichments of kinase genes were 
visualized in a heatmap format. On the x-axis were kinase genes and on the y-
axis GO-BP classes. The x-axis was clustered by using binary distance and 
complete linkage whereas the y-axis was clustered by using Lin semantic 
similarity metric [121] and Ward linkage metric. Black color indicates that in 
the co-expression network of the kinase gene in question the GO-BP class in 
question is statistically significantly enriched. Individual GO-BP classes were 
grouped under a representative name for the sake of readability. 
7.6.3. Body-wide gene expression heatmaps 
Similarly to provide an overview of the expression of an entire gene family 
across healthy and pathological tissues specific style of heatmap visualization 
was developed. This bodymap contains the mean expression values of chosen 
genes (x-axis) in 111 human in vivo tissues (y-axis). The cells of the map have 
been colored so that red indicates high expression and blue low expression. 
The mean values of the genes were centered by subtracting mean for the gene 
and scaled by dividing with the root-mean-square. The number of samples 
available for each tissue is shown in the parentheses. Both axes of the map 
have been clustered (Euclidean distance with ward linkage) so that tissues 
resembling each other the most are closest to each other, and similarly, genes 
with most similar expression patterns are placed adjacent to each other. These 
plots have been used in publication I. Differently to that, in publication III we 
used a heatmap with binarized expression levels. There clustering was based 
on binary distance and complete linkage The complete linkage tree building 
algorithm used in publication III provides larger clusters and is more suitable 







8.1. Constructing GeneSapiens 
We collected 9783 Affymetrix CEL files from public sources, which were then 
used to construct a synthesis of genomewide expression profiles across 175 
different healthy and pathological tissues. As same CEL files might have been 
used in multiple studies their uniqueness was tested by using cyclic 
redundancy check algorithm. Further steps in the construction of the database 
can be divided into data integration and annotation. 
 
 
Figure 2 Schematics of constructing integrated Affymetrix gene expression dataset. A) 
MAS5 is used as a preprocessing method performing both background correction and 
combining probe level data into a gene level data (with alternative CDF-files), B) 
Alternative CDF-files are used to link probe level data directly into a gene level data, C) 
Equalization transformation is used to perform samplewise normalization, D) Array gene 
centering (AGC) is used to perform genewise normalization across array generations, E) 
Each sample is then linked with curated annotation of biological details of the hybridized 
sample, F) Each gene is further annotated from suitable resource (like Ensembl [122]). 
8.1.1. Data integration 
As a first step in data integration, raw data from CEL files was preprocessed 
using MAS5. Alternative CDF files were used to map probes directly to 
Ensembl gene ids (Figure 2A-B). When using alternative CDF-files all the 
probes identifying a gene with high enough specificity effectively form one 
large probeset [70]. The usage of these files provide significant benefits as a 
more up to date genome build is taken into account when defining which gene 
each probe measures, and ultimately, each gene can be assigned with only one 
expression value in each sample. 
 
As shown by Canales et al. [53], Nimgaonkar et al. [57], Hwang et al. [56] and 
Autio et al. [58] varying probe sequences (Figure 3A) is one of the main 
sources of technical variation between array generations. It seems that a 
change of even a single nucleotide affects the hybridization efficiency of the 
probe enough to cause a noticeable change in the final expression value. This 
level of sensitivity is usefull to calculate stray signal estimate from Mismatch 
probe data. However, even completely complementary probes for a gene can 
be major source of noise if they measure different parts of the sequence of the 
gene. For example, when measuring a single mRNA sample with two different 
array generations (HG-U95 and HG-U133A) the correlation coefficient 
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probes based on the sequence overlap (between the probes of the array 
generations) the correlation coefficient systematically increases (Figure 3B). 
While this approach provides viable solution for incomparability of results 
between different array generations it remains impractical as the number of 
genes remaining in the analysis rapidly decreases (Figure 3B). The reasons for 
this probe sequence dependent noise are multiple. For certain, a part is caused 
by different hybridization kinetics of different nucleotide sequences, but the 
issue of alternative splicing is also involved. Various array generations might 
actually measure different splice variants of the genes and therefore produce 
different expression values. Irrespective of the reasons, the probe sequence 
dependent noise might have a wider impact on various molecular genetic 
measurement technologies than is generally known. 
 
 
Figure 3 A) Conceptual drawing of four different oligonucleotide probes from two 
different Affymetrix array generations. Each probe hybridizes to a different part of the 
sequence of the gene and therefore has varying amounts (0-25 bp) of overlapping 
nucleotide sequences with the probes of another array generation. B) The black line 
depicts the effect of varying probe sequence overlap on correlation between replicate 
analysis of same RNA sample on two array generations, HG-U95 and HG-U133. The blue 
line depicts the number of genes remaining in the analysis after filtering the probes based 
on nucleotide sequence overlap between array generations. Figure produced from the 





































This approach of probe filtering based on sequence overlap has been utilized 
in one form or another in a few array meta-analysis studies [56, 71] but as our 
aim was to build a comprehensive transcriptomic resource by using data from 
multiple array generations the probe filtering approach was not viable option, 
mainly due to the impossibility of finding a reasonable set of overlapping 
probes between several array generations. For example, to achieve correlation 
coeffiencient of 0.8 between replicates one would need to use only probes with 
complete 25 bp overlap and that would drop the amount of genes to less than 
5000. Additionally, the expression level of each gene would be derived from 
significantly smaller number of probes, thus the noise can be assumed to 
increase substantially. 
 
Instead we studied another approach utilizing the large data collections to 
correct for probe level noise. In theory, one can assume each gene to have 
certain biologically meaningful range of expression values, a certain minimum 
background expression level and a certain maximum level where it is 
expressed as actively as possible. Then, if one has a large enough collection of 
genome wide expression data one can assume to have this biologically 
meaningful range of expression values covered. In other words, with a certain 
accuracy one might assume the distribution of expression values of each gene 
to cover all biologically sensible expression levels (states). Then, given this 
amount of data from each array generation one is able to identify a major 
portion of the noise caused by probe sequence effects by comparing the 
expression value distributions of genes between the array generations (Figure 
4A-B). This method was named as Array Gene Centering (AGC) and we were 
able to show it to work well enough to perform genewise correction of noise 
caused by varying probe sequences. The normalization was considered to 
perform well enough if in normalized data biological variation clearly 
surpassed the technical variation. This would allow biological conclusions 
drawn from the data. Actually, it is reasonable to assume that AGC 
compensates for a variety of sources of noise when comparing different array 
generations, not only for probe sequence effects. As AGC is based on few 
simple assumptions about the distributions it should be applicable for 
normalizing other high-throughput data as well.  
 
 
Figure 4 The effect of AGC correction to the data of a single gene. A) Histogram of 
expression value distributions of the gene across four array generations before AGC 
correction. B) Histogram of expression value distributions of the gene across four array 




















































The normalization of GeneSapiens data was two-dimensional (Figure 5A-B). 
Samplewise normalization with Equalization transformation (EQ) was done to 
correct for technical variation between samples (Figure 2C and Figure 5A). 
The parameters of the distribution to which data was normalized with EQ 
(mean=8, standard deviation=2) were selected based on the entire dataset of 
9783 samples. Application of AGC as genewise correction for EQ normalized 
data (Figure 2D,Figure 5B) resulted in one final expression value per gene per 
sample, altogether 113 786 107 gene expression values. See materials & 
methods as well as publications I and II for more details on data integration. 
 
 
Figure 5 Schematics of two-dimensional normalization scheme used in the GeneSapiens. 
A) Each sample is normalized with equalization transformation (EQ) B) Each gene is then 
corrected with array gene centering (AGC). 
8.1.2. Annotation 
In the data annotation part the first step was to manually curate the 
annotation of each sample. For this purpose we defined 37 annotation fields to 
be filled for each sample. Naturally, the accuracy of annotation depends on the 
quality and accuracy of the annotation provided by the original authors. For 
the primary annotation of GeneSapiens we manually curated altogether 
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importing algorithms. On average each sample has 18 manually curated 
annotation details. Table 1 describes the most important biological annotation 
fields used in primary annotation. 
 
Table 1 Description of 17 biologically most relevant annotation fields used to describe 
each sample. The data analysis and secondary layer of annotation rely on these listed 
fields. 
Name of the field Description of the field Percentage of 
samples having 
the information 
Exp type Divides samples into healthy, 
malignant and other disease 
classes 
100 
Anatomy Anatomical system from which 
the sample originates 
100 
Cell type Cell type from which the sample 
originates 
60.5 
ICD10 ICD10 code describing the 
pathological status of the sample 
79.9 
ICDO ICD-O code further specifying the 
type of malignancy 
67.6 
Tissue preparation Definition of sample preparation 
type 
96.6 
Age Age of a person from which the 
sample originates 
43.7 
Sex Sex of a person from which the 
sample originates 
58.6 
Ethnical background Ethnical background of a person 
from which the sample originates 
18.7 
T-stage Tumor-stage of a sample 
(malignant) 
19.7 
N-stage Nodal-stage of a sample 
(malignant) 
24.4 
M-stage Metastasis-stage of a sample 
(malignant) 
21.3 
Grade Grade of a sample (malignant) 28.2 
Histology Detailed histological information 
of the sample 
33.3 
Vital status Information whether the patient 
was alive or not at the time of the 
sampling 
28.4 
Survival day Days the patient survived 13.2 
Comment Further notes about the sample 43.5 
 
A secondary layer of annotation was done by grouping samples having 
specified combinations of primary annotations into groups of samples. This 
secondary layer of annotation formed 1215 groups of samples usable for data 
analysis purposes. The secondary layer of annotation specifically allowed 
relatively easy way of analyzing samples on various levels of biological systems 
(e.g. breast cancer as one group and various histological subtypes of breast 




8.2. Validation of GeneSapiens 
GeneSapiens data was validated with both mathematical and biological 
methods. 
8.2.1. Mathematical validation 
The issue of defining goodness of normalization as well as goodness of entire 
data integration procedure was one of the key questions to be solved. On the 
side of more mathematical validation we found out that multidimensional 
scaling (MDS) can provide a rather good overview as it is able to provide 
visually informative plot of the overall clustering tendency of the data. The 
original problem of array generation driven clustering of data is clearly visible 
from the MDS analysis as well as is the effect of the normalization. This is 
demonstrated in Figure 6 which shows a 2-dimensional representation of a 
Pearson correlation coefficient based distance matrix of 1489 healthy in vivo 
samples. The same set of samples has been analyzed after three different 
normalization steps (MAS5, EQ and AGC). It is clear that when this set of 
samples has been preprocessed with MAS5 the clusters of samples are defined 
largely by the array generations (Figure 6A). After EQ, the clusters are 
perhaps slightly more compact, but still defined by array generations (Figure 
6B). However, after AGC correction we can see a dramatic mixing of array 
generations among the clusters suggesting that some other feature of the data 
defines the clusters (Figure 6C). When we examine the clusters of AGC 
corrected data in terms of anatomical origin of samples we can see that 
clusters are formed definitely more in terms of anatomical origin of the 
sample than the array generation of the sample (Figure 6D). 
 
Figure 6 Two-dimensional multidimensional scaling of Pearson correlation coefficient 
based distance matrix between 1489 healthy in vivo samples. A) Samples after MAS5 
preprocessing colored by the used array generation B) Samples after EQ normalization 
colored by the used array generation C) Samples after AGC correction colored by the used 
array generation D) Samples after AGC correction colored by the anatomical origin of the 
sample. 
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In publication I we performed a more exact quantification of the sample 
clustering before and after AGC correction by K-means clustering of the data. 
Subsequent rand index calculation [116] revealed that the index of sample 
segregation into the array generation based clusters decreased from 0.45 to 
0.15 (where 1 indicates perfect segregation) after the correction. Conversely 
sample segregation based on the anatomical system of origin increased from 
0.22 to 0.92. 
 
In publication I we also studied correlations between technical replicates of 
the same samples analyzed by different Affymetrix array generations. 
Correlation coefficients between 14 human muscle biopsy samples analyzed 
on U95Av2 and U133A array types increased to >0.9 after AGC correction 
whereas before the correction coefficients were <0.75. Another study 
contained 123 leukemia samples analyzed on three array types (U95Av2, 
U133A and U133B) [123, 124]. We found out that mean value of correlation 
coefficients between the replicates was significantly higher (0.78) than mean 
value before the correction (0.5). 
 
In publication II we further tested the performances of various normalizations 
with multiple measures of goodness. Altogether 6926 Affymetrix samples 
were preprocessed with MAS5 and then normalized by five different methods; 
standardization (Z), housekeeping gene based (HK), equalization 
transformation (Q), Weibull distribution based normalization (WBL), array 
generation based gene centering (AGC). Out of these we formed ten different 
combinations i) pure preprocessed MAS5.0 ii) Z iii) Q iv) WBL v) HK and all 
these combined with AGC (MAS5AGC, ZAGC, HKAGC, QAGC, WBLAGC). 
This collection of data contained more than 500 samples from five different 
Affymetrix array generations (HU6800, U95A, U95Av2, U133A, U133 Plus 2). 
 
The goodness of normalization was defined in five different ways 1) 
correlation between technical replicates 2) correlation between randomly 
selected genes 3) classification of the samples based on the anatomical class 4) 
comparison of correlations between the samples computed based on the 
anatomical classes and array generations 5) stability of the housekeeping gene 
expression levels. 
 
First measure of normalization goodness was done by calculating correlation 
coefficients between technical replicates by using same set of 123 leukemia 
samples [123, 124] as was used in the publication I. This method of data 
comparability has been used in several studies [56, 57, 71]. MAS5, Z and HK 
gave identical results since the methods are linearly invariant while WBL gave 
slightly better correlation coefficient. However, combining any of these 
methods with AGC resulted in significant increase in correlation coefficient 
value (Publication II, Figure 1). WBLAGC gave the best correlation coefficient 
but the difference to other AGC combined methods was not significant. 
 
The second measure of normalization goodness was based on testing 
correlation coefficients of randomly selected gene pairs. The assumption here 
is that randomly selected genes should not be correlated with each other, thus 
the expected value for their correlation is zero. Technical variation from 




reflects as non-zero correlation between random gene pairs. We calculated 
correlation coefficients between 500 randomly chosen genes, each having 
values in all array generations, from data normalized with previously 
described ten methods. Results showed that ZAGC, HKAGC, QAGC and 
WBLAGC had values significantly closer to zero than other methods 
(Publication II Figure 2). 
 
The third measure of goodness of normalization assumed that the expected 
value of correlation coefficient between samples from the same anatomical 
class is higher than the expected value of correlation coefficient of samples 
from different anatomical classes, even if the samples originate from same 
array generation or experiment series. For this purpose we calculated 
correlation between all 1464 samples and divided the results in two groups 1) 
correlations of samples from the same array generation but different 
anatomical class 2) correlations of samples from the same anatomical class 
but different array generations. Results showed that without AGC the array 
generation was stronger than anatomical class in defining the identity of the 
sample. However, when AGC was used correlation coefficients between the 
samples of same anatomical origin had significantly higher correlations than 
between samples from different anatomical origin and from the same array 
generation (Publication II Figure 3). 
 
Stability of housekeeping genes was used as the fourth measure of 
normalization goodness. This is based on the assumption that there is a set of 
genes of whose products are needed for the basic metabolism of all cells and 
therefore the expression levels of these genes are relatively stable. We used 
126 of these so-called housekeeping genes [24] to measure the goodness of 
normalization by assuming that the better the normalization the more stable 
the housekeeping gene expression is. For each of the genes we calculated 
Kullback-Leibler distance between the distribution of expression values in one 
array type and the distribution of expression values across all array types. 
After AGC, normalization distributions of housekeeping genes in the different 
array generations resemble more the combined distribution across all array 
generations, in other words, the expression of housekeeping genes is more 
stable after AGC (Publication II Figure 4). 
 
The fifth measure of normalization goodness was performed by classifying 
samples to the anatomical systems of origin with nearest neighbor classifiers. 
For each anatomical system of origin (n=35) the mean expression profile of 
logarithmic expression values was calculated, with each anatomical system 
having at least 10 samples. This analysis was limited to 1464 healthy tissue 
samples present in the dataset, as the malignant tissue samples might have 
caused severe bias for classification according to anatomy. Each sample was 
then classified into most similar anatomical system with nearest neighbour 
algorithm. Normalization methods with AGC achieved substantially higher 
accuracies with average accuracy of 89% versus 76% without AGC 
(Publication II Table 1). 
8.2.2. Biological validation  
In publication I we used genes with known tissue specific expression profiles 




seven genes with well-known tissues-specific expression. Troponin T type 2 
(TNNT2) shows very clear heart specific expression, as expected for a 
clinically used cardiac biomarker, even though data originated from four 
different array generations and comprises only about 0.5% of the samples. 
High expression of TNNT2 in rhabdomyosarcoma was also found out to 
correspond with observation of increased troponin T levels in serum of 
rhabdomyosarcoma patient [125]. Similarly the body wide expression profile 
of placental alkaline phosphatase (ALPP) shows the known expression in 
placenta [126] and also confirmed the known ectopic expression [127, 128] in 
various types of cancers. Myelin-associated glycoprotein (MAG), a known 
neuronal marker [129] shows high expression in healthy central nervous 
system and to some extent in gliomas. Similarly Kallikrein- 3 (KLK3), Glial 
fibrillary acidic protein (GFAP), Insulin (INS) and L-lactate dehydrogenase C 
(LDHC) show corresponding known tissue specific expression in prostate 
[130], nervous system [131], pancreas and testis [132], respectively. Further 
biological validation was acquired by using GeneSapiens for studies III and IV 






Figure 7 Body wide expression map of seven genes with known tissue specific expression. 
On the x-axis are genes (MAG, GFAP, KLK3, INS, LDHC, TNNT2 and ALPP) whereas on 
the y-axis are 111 healthy and malignant tissues (number of samples per tissue is given in 
the parentheses). Data has been scaled genewise and both axes have been clustered 
hierarchically with Euclidean distance and Ward linkage. Color indicates the average 
expression of the gene in the tissue in question. 
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8.3. Application of GeneSapiens data 
GeneSapiens data is essentially two dimensional, the expression values of 
17330 genes across 9783 samples, with some covariate data associated to both 
dimensions. Therefore the application of GeneSapiens data is best to be 
understood as analyses of either the gene or sample dimension. 
8.3.1. Gene dimension analyses 
The first application of GeneSapiens data was to study how various individual 
genes are expressed across the whole human body. In publication I we showed 
the bodywide expression profile of preferentially expressed antigen in 
melanoma (PRAME), a gene having high expression in healthy testis but also 
showing high ectopic expression in various human cancers (Publication I 
Figure 4). Even though the high expression in various human cancers was 
already known [133] the benefit of large-scale data integration is obvious as it 
comprehensively reveals all the tissues where the gene is expressed. One of 
the key challenges of genome wide gene expression measurements has been 
the difficulty of finding a proper reference for the interpretation of expression 
values. An ability to put expression level into the context of thousands of other 
properly annotated samples provides a robust reference for interpretation. 
Specifically the body wide dot plot allows visualization of thousands of data 
points in a biologically sensible manner. 
 
In publication I we performed gene family analysis by creating a bodymap of 
expression values of genes listed in Sanger Center cancer gene census 
(Publication I Figure 5). This heatmap style of data analysis and visualization 
allows one to identify subgroups of genes or tissues having common 
expression profiles. In principle, the bodymap combines both the gene and 
sample dimension analyses of GeneSapiens data. As one might imagine the 
expression profiles of human cancer genes divided tissues into malignant 
(84.4% malignant tissues), healthy (82.1% healthy tissues) and to 
hematological (100% hematological tissues) clusters. Somewhat surprising 
was the observation that hematological cluster contained both healthy and 
malignant tissues without apparent division. The gene dimension revealed 
five distinct clusters of cancer genes. To interpret potential functional 
differences of gene clusters we calculated correlation coefficients between the 
cancer genes and known marker genes antigen KI-67 (MKI67), proliferating 
cell nuclear antigen (PCNA), cytokeratin-19 (KRT19) and leukocyte common 
antigen (PTPRC) across the entire database. Cancer genes correlating with 
proliferation markers, MKI67 and PCNA, were the ones with unusually high 
expression in solid malignancies. KRT19 correlated mainly with epithelial 
cancers. And as one might assume genes correlating with the hematological 
marker PTPRC were most often expressed in hematological malignancies. 
 
The bodymap of human cancer genes pinpointed several genes with extremely 
high expression. One example of this was the Mast/stem cell growth factor 
receptor (KIT) with extremely high expression in gastrointestinal stromal 
tumors (GIST) (Publication I Figures 5 and 6). This is a prime example of how 
having a comprehensive expression profile allows one to identify the extreme 
high expression of a gene in a malignancy of which the healthy counterpart 
samples are hard to get. It suggests that the gene in question might have a 




therapeutic angles. High expression in this case most likely is not cancer 
specific, as it is likely that interstitial cells of Cajal, from which GIST is though 
to originate [134], also express KIT at high level, but the extreme expression 
suggests that these cells are highly dependent on KIT. GIST patients often 
have mutated KIT and Gleevec has been found to be effective drug targeting 
KIT in addition to its primary target, the BCR-ABL fusion gene. Similarly 
bodywide expression profiles of the ETS oncogene family (FEV) and the 
Myeloid/lymphoid or mixed-lineage leukemia (MLLT11) allowed us to identify 
high expression in various malignancies. The key conclusion is that many of 
these observations are only possible with the ability to interpret expression 
levels in the context of a bodywide collection. 
 
In publication III we performed an even more extensive analysis of the 
bodywide expression profiles of 459 human kinases. We defined the concept 
of transcriptionally active genes by analyzing the expression levels of kinase 
genes across 1603 healthy samples representing 44 tissues. By using entropy 
based methodology we were able to define an expression level threshold for 
each kinase gene above which the gene can be assumed to be under active and 
positive regulation. This is based on the assumption that after integrating data 
from multiple tissues together we are able to define the background 
expression level shared by most tissues. After defining the transcriptional 
activity thresholds for all kinase genes we were able to binarize the expression 
levels of kinase genes over 99 tissues into transcriptionally active/inactive 
states (Publication III Figure 1A). Hierarchical clustering of the tissues 
revealed that the binary expression state of human kinome is informative 
enough to create an overall similar threefold separation to healthy, malignant 
and hematological tissues as seen in the bodymap of human cancer genes 
(Publication III Figure 1B). However, an additional mixed cluster was formed 
containing some healthy-malignant pairs not separable from each others 
based on their kinase profile. There were also distinct subclusters of neuronal 
and muscular tissues among the healthy ones whereas solid tumors had 
subclusters of non-epithelial and epithelial tumors, the latter further 
subdiving into adeno- and squamous types. Interestingly, the human kinome, 
which is strongly regulated at the protein level, is also under strong enough 
transcriptomic regulation to define tissue type only based on the profile of 
transcriptionally active kinase genes. Distinct clustering of various tissue types 
suggested that transcriptional activity levels provided biologically solid data. 
 
We were also able to identify several groups of kinases having distinct 
transcriptional activity profiles across the tissues (Publication III Table 1). The 
most prominent one was named “proliferation” kinase genes as it was mainly 
active in solid tumors and immunological/hematological tissues. Kinases of 
that group were transcriptionally active in 88.7% of solid cancers and in 
65.8% of immunological/hematological tissues. In the healthy and mixed 
tissue groups the percentages were 20.8% and 44.2%, respectively. Other 
identified groups of kinase genes included “hematological”, “neuronal, ”non-
epithelial”, “epithelial” and “generally active”. 
 
The same methodology of defining transcriptional activity can be applied 
across the entire human transcriptome to define which genes are assumed to 




the results of such an analysis performed for each gene in all healthy tissues. 
The figure itself provides only an overview of the transcriptomic activity of 
human genome across 44 healthy tissues. 
  
Further analysis of the transcriptional activity levels shows that the majority 
of genes are transcriptionally active in less than 50% of healthy tissues but 
there are also nearly 2000 genes (11.5% of all genes) transcriptionally active in 
virtually all tissues (Figure 9A). This number is slightly less than recently 
estimated by Zhu et al.[135], but it is largely a threshold issue. In publication 
III clustering of human tissues in terms of binary transriptional activity 
profile revealed distinct clusters. Similarly, usage of the binary transcriptomic 
activity profiles of all genes as a basis for clustering of 44 healthy tissues 
revealed an anatomically logical clustering of tissues (Figure 9B). 
 
Figure 8 Transcriptional activity map of 17 
330 genes across 44 healthy human 
tissues. Black indicates that a gene is 
transcriptionally active in the tissue in 
question. Grey indicates missing data for a 
gene in the tissue in question. Both axes 
have been clustered with binary distance 
metric and complete linkage method. 
Figure is provided only as an overview of 
the transcriptomic activity as the amount 
of data greatly surpasses the resolution of 






Figure 9 Characteristics of healthy transcriptome across 44 tissues. A) Number of genes 
transcriptionally active in healthy human tissues presented as percentage of all 44 tissues 
present in the study. For example there are approximately 2000 genes that are active in 
at least 90% of the tissues. B) Similarities between 44 healthy human tissues in terms of 
their binary profile of transcriptionally active genes. The tree has been build upon binary 
distances with Ward linkage method and with the Analyses of Phylogenetics and 
Evolution (ape) R library [136].  
Transcriptional activity status can also be easily used to identify new 
biomarkers. An example of such an analysis is shown in Figure 10 consisting 
body wide expression profiles of the top 50 most healthy tissue specific genes. 
The group of genes has been selected by requiring that they are 
transcriptionally active in no more than three healthy tissues and further 
prioritized by highest median expression level above the transcriptional 
activity level threshold. Analyses like this easily reveal known tissue 
biomarkers like KLK3, Tissue kallikrein-2 (KLK2), TNNT2 and Troponin I 





















































































































































Figure 10 A bodymap of the top 50 most tissue specific genes. On the x-axis are genes 
whereas on the y-axis are 44 healthy tissues (number of samples per tissue is given in 
parentheses). Data has been scaled genewise and both axes have been clustered 
hierarchically with Euclidean distance and Ward linkage. Color indicates the average 
expression of the gene in the tissue in question. 
In publication III we also studied the genomic co-expression environment of 
all kinase genes in order to find out with which biological processes they 
associate (Publication III Figure 2). Results showed that for most of the 
human kinase genes it is possible to find significant enrichments of biological 
processes, as defined by the Gene Ontology (GO-BP) [137], present in the 
genomic co-expression network around the kinase genes. Proliferation related 
kinase genes identified from transcriptional activity data were found to 
associate with DNA repair, cell cycle control, mitotic chromosome handling, 
chromatin handling and regulation of cell growth. This group of genes 
included the well-known mitotic kinase genes like Aurora kinase A (AURKA) 
[138], mitotic checkpoint serine/threonine-protein kinase (BUB1) [139], Polo-
like kinase 1 (PLK1) [140], Dual specificity protein kinase (TTK) [141], cyclin-
dependent kinase 1 (CDC2) [142], MAPKK-like protein kinase (PBK) [143], 
Mitotic checkpoint serine/threonine-protein kinase beta (BUB1B) [144], Polo-
like kinase 4 (PLK4) [145], NimA-related protein kinase 2 (NEK2) [146], 
Serine/threonine-protein kinase Chk1 (CHEK1) [147], Aurora kinase B 
(AURKB) [148], Cell division protein kinase 2 (CDK2) [148], but also several 
novel ones like Microtubule-associated serine/threonine-protein kinase-like 
(MASTL), Maternal embryonic leucine zipper kinase (MELK), Dual specificity 
tyrosine-phosphorylation-regulated kinase 2 (DYRK2), DNA-dependent 
protein kinase catalytic subunit (PRKDC) which are not yet experimentally 
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8.3.2. Sample dimension analyses 
In publication IV we explored a methodology allowing one to “align” an 
expression profile to a reference database of expression profiles. The specific 
aim of this capability is to enable interpretation of the “query” expression 
profile in the context of the existing expression profiles. This resulted in the 
development of the method for alignment of gene expression profiles (AGEP). 
The principles of the method are explained in Figure 11. 
 
 
Comparing an individual test sample against the reference database results in 
two matrices of gene and reference tissue specific scores (tm- and ts-scores), 
as seen in Figure 11C-D. In short, tissue match scores (tm-scores) describe 
how well the expression levels of genes in the test sample match the expected 
expression levels in the reference tissues. The tm-scores vary between 0 and 1, 
where 0 means “no-match” and 1 means “perfect match”. Tissue specificity 
scores (ts-scores) describe whether the match was tissue specific or not. The 
ts-scores vary between -1 and 1, where -1 means “not matching tissue specific 
expression level” and 1 means “matching tissue specific expression level”. In 
publication IV we showed multiple ways how these scores can be used to 
interpret the nature of the test sample expression profile. See material and 
methods and publication IV for further details. 
 
As a validation of the accuracy of the method we tested its ability to identify 
the tissue of origin of the query samples (origin defined as the reference tissue 
with highest average ts-scores). This was done both as a leave-one-out cross-
validation (LOOCV) analysis [149] for the entire reference database and for an 
external dataset of 195 samples from the Array Express study E-GEOD-7307. 
In LOOCV analysis all samples of the reference database were tested one by 
one as if they were external samples. It is essential for LOOCV that the sample 
tissue 1
tissue 2
Density estimates for all genes
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Figure 11 Schema of the AGEP 
method. A) An external test 
sample is compared to density 
distributions calculated from 
the reference data tissues. B) 
At the individual gene level 
the method calculates the 
range of the density estimate 
where the density is lower 
than the density value of the 
expression in the test sample. 
The result is called as the 
tissue match (tm-) score 
(0<tm-score<1). C) The 
calculation is repeated for all 
genes of the test sample 
against all reference tissues 
resulting in a matrix of tm-
scores. D) The tm-scores of 
each gene against all 
reference tissues are further 
compared together to analyze 
uniqueness of the tm-score 
value resulting in a matrix of 






being tested is removed from the reference data before testing. Overall 
accuracy with LOOCV was 93.6% (with a range of 58.3-100% depending on 
tissue type) and with external dataset tissue of origin was correctly identified 
for 84.6% of samples and for 12.3% of samples a closely related tissue type 
was identified (actually this 12.3% of samples consists entirely central nervous 
system (CNS) samples where different anatomical parts of brain are mixed) 
(Publication IV Table 1 and Supplementary figure 2). Altogether AGEP was 
found to be at least as accurate in identifying the tissue of origin as the more 
simpler nearest-neighbor (NN) [150, 151] and the more complex support 
vector machine (SVM) [152-154] based algorithms (Publication IV Table 1). 
 
One of the key features of AGEP is its ability to quantify the similarity of the 
query profile to the reference tissues at the level of genes. This allows one to 
study gradual changes in the transcriptomic program for example during the 
differentiation of cells. In this particular example seven samples, each 
representing a distinct state of myeloid cell differentiation, were compared 
against hematopoietic stem cell (HSC), granulocyte and monocyte reference 
tissue classes (Publication IV Figure 6). As one might assume, the 
hematopoietic stem cell sample had the largest amount of genes having HSC 
stem cell specific expression levels. In a somewhat more differentiated 
myeloblast sample HSC specific expression levels of genes disappear and the 
sample represents more “in between” type of profile than anything specific. In 
the monocyte differentiation line in the monoblast sample some genes gain 
monocyte specific expression levels and resembles monocytes somewhat 
more, whereas the monocyte sample, as presumed, has the most monocyte 
specific expression levels. Similarly when moving from myeloblast to 
granulocyte the sample gets most granulocyte specific expression levels. On 
the malignant side, interestingly, the leukemia stem cell sample resembles 
HSC, but an AML sample seems to resemble a non-stem cell like 
transcriptome with differentiation direction not similar to granulocyte or 
monocyte. 
 
We also used AGEP to compare a series of samples from an experiment of the 
differentiation of mesenchymal stem cells (MSC) against the reference 
database (Publication IV Figure 4-5 and Supplementary figure 4). The aim of 
the experiment had been to study of adipogeneic differentiation and we were 
able to show that samples change their transcriptomic program towards 
adipose tissue during the differentiation process. AGEP also allowed us to 
identify key genes changing during the differentiation. Proteoglycan link 
protein (HAPLN1), Stanniocalcin-2 (STC2), Ajuba isoform 2 (JUB) and 
Dickkopf-related protein 1 (DKK1) had relatively MSC cell specific expression 
levels in all replicate samples at timepoint 0h. After seven days of 
differentiation Adiponectin precursor (ADIPOQ), Lipid droplet-associated 
protein (PLIN), Thyroid hormone-inducible hepatic protein (THRSP) and 
MOSC domain-containing protein 1 (MOSC) gained expression levels 
matching expression levels relatively unique for adipose tissue. All these are 
previously known to be adipose tissue related genes [155-158].  
 
The change in the expression level of ADIPOQ is shown in more detail in the 
Figure 12. At the 0h timepoint all replicates had such an expression level of 




many tissues. At the 7d timepoint all replicates had gained an adipose tissue 
specific expression level for the gene. Table 2 summarizes how these changes 
are reflected in the scores provided by the AGEP method when comparing 
sample replicate A against MSC and adipose tissue at 0h and 7d timepoints in 
terms of ADIPOQ gene. The key observation is that the tm-score for MSC 
drops from 0.99 to 0, reflecting the loss of an expression level matching MSC 
(and most of the other tissues). Similarly, the ts-score for adipose tissue 
increases from -0.2 to 0.9, reflecting the gain of adipose tissue specific 
expression level. The relatively high tm-score against adipose tissue at the 0h 
timepoint (0.78) points to some over sensitivity of the method to emphasize 
the meaning of individual data points of the reference data. The most likely 
cause for the high tm-score in this case is a single adipose tissue sample 
within the reference data with low expression for the gene in question. 
 
Figure 12 ADIPOQ expression levels in normal tissues, with 6 mesenchymal stem cell 
(MSC) samples included (on the right). There were three replicates of timepoint 0h 
samples, highlighted in light red, and three timepoint 7d samples, highlighted in light 
blue. At timepoint 0h each sample had ADIPOQ expression level typical for most of the 
tissues. On the contrary, after seven days of differentiation towards adipocytes, samples 
obtained adipose tissue specific expression levels.  
Table 2 Tissue match and tissue specificity scores of ADIPOQ gene when comparing MSC 
replicate A against mesenchymal stem cells and adipose tissue at 0h and 7d timepoints. 
 Timepoint 0h Timepoint 7d 
MSC tm-score 0.99 0 
MSC ts-score 0.02 -0.18 
Adipose tissue tm-score 0.78 0.95 
Adipose tissue ts-score -0.20 0.9 
 
In publication IV we also showed how analyses at the individual gene level can 
be extended to gene sets to understand the changing transcriptomic program 
at the level of biological processes or pathways. For example, in terms of the 
geneset of adipose tissue differentiation and the geneset of lipid and fatty acid 
transport the 0h time point sample had expression levels mostly matching 
those typical for MSC. After seven days of differentiation, samples mostly 
resemble adipose tissue at the tissue level with both genesets having 
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The need for data integration is as natural as the scientific understanding of 
complex phenomena is possible only with comprehensive and accurate data 
collections. The integration of large amounts of transcriptomic data has been 
the aim of many studies and many have also succeeded in it [17-20, 80-83, 
85], gaining further understanding of biology of gene expression. 
 
The results presented here comprise one of the most comprehensive and most 
integrated transcriptomic data sources constructed so far. In publication I we 
described how GeneSapiens database was constructed from 9873 in vivo 
samples. The major challenges in the transcriptomic data integration were the 
variance in data annotation nomenclature as well as the technical variation in 
how different array generations measure expression of genes. The enormous 
complexity of biological organisms ensures that no two samples are exactly 
alike, however there needs to be some sort of systematic way to describe what 
kind of sample has been hybridized on the microarray, so that  at least semi-
equivalent samples can be identified. Additionally, for biologically sensible 
datamining one needs the ability to identify samples belonging to various 
hierarchical levels of biological classification of anatomical systems, organs 
and tissues. These requirements render current computational annotation 
methods ineffective and inaccurate as there are not enoughly sophisticated 
algorithms to handle true complexity of the sample annotation.  Thus, we used 
manual curation as the main method of annotation. Automation with 
computational tools was used as much as possible without compromising 
accuracy. Altogether this scheme of annotation has most likely produced the 
most accurate collection of transcriptomic data so far. However, one must 
understand that the collected and integrated data is essentially only as reliable 
and usable as its annotation in the original study is. We noticed large quality 
differences in the annotation details given by the original authors, also newer 
studies were found to have a significantly higher quality of annotation data 
available when compared to studies published several years ago. It is hard to 
say whether it is due to standards like MIAME [75] being slowly adapted by 
the scientific community or general increased awareness that expression data 
could be useful also in contexts other than the original experiment setup. 
 
The major source of technical variation was different hybridization kinetics of 
varying probe sequences in different array generations, as pointed out by 
Hwang et al. [56], Elo et al. [71], Canales et al. [53], Nimgaonkar et al. [57], 
Mecham et al. [72], Autio et al. [58]. The breakthrough in our research was 
the discovery that after having enough expression data across a multitude of 
tissues from each array generation one could actually observe the entire 
biologically occurring spectrum of expression values for a gene. This leads to 
the possibility of identifying technical variation in the array generations’ 
ability to measure the expression of a gene in the form of differences in the 
distributions of expression values of the gene between array generations. 
Apart from the solution presented by Hwang et al. and Elo et al. [56, 71] 
where data from multiple array generations are integrated by using only 
probes with common sequences, the AGC correction presented in the 
publication I remains the only known solution for the problem. The largest 




is not large enough then expression distributions used in the correction 
inadequately represent the complete biological variation of the expression of 
genes. In this kind of case some part of the biological variation would be 
corrected as if it were technical variation and therefore bias would occur in the 
data. Unfortunately, there is no easy way to know when this happens, but the 
larger the used data collection is, the less likely it is to happen. It will be a 
highly interesting avenue of research to find out how much data is actually 
needed to define the range of virtually all-possible biologically meaningful 
expression levels for each gene in each possible tissue. 
 
Another potential hazard still present in the GeneSapiens data is variation 
caused by different sample preparation and hybridization protocols. Currently 
used normalization schemes are unable to compensate for that kind of 
variation if it causes non-linear changes between genes´ measured expression 
values. Another caveat is the type of sample taken from in vivo tissues; a bulk 
sample invariably contains multiple cell types whereas microdissected 
samples contain preferentially only single cell type. The former sample 
represents congregate expression levels over all the cell types whereas a 
microdissected sample contains more purely the expression levels of a single 
cell type, therefore microdissection can give much higher expression levels for 
genes specific for the single cell type when compared to bulk samples where 
other cell types average out the expression levels. This returns back to the 
accuracy of sample annotation, neither the bulk or microdissected samples 
should be assumed to be wrong in any particular way but should not be 
treated equally in terms of their representation of the tissue in question. 
Fortunately, large amount of data can give some level of quality control even 
against problems like this, since if a single study behaves completely 
differently from others it should be subjected to further scrutiny. 
 
Understanding the expression levels among the large collection of data 
highlights the key advantage of integrating transcriptomic data. By comparing 
expression values to a large collection one is able to put those into context and 
understand what is really “high” and “low” from the otherwise relatively 
enigmatic values. The best example of this is the identification of biomarkers 
as shown in the publication I. KLK3, MAG and TNNT2 could not be declared 
as tissue biomarkers with any reasonable level of specificity without 
knowledge of how the expression in the tissue in question relates to other 
tissues. With biomarkers, tissue or pathology specific expression is the key 
question, but when studying the expression levels of genes targeted by existing 
drugs highly interesting question is whether there is some other pathological 
condition with a similar expression level as the one already treated with the 
drug. In other words, if a gene is an optimal drug target in some pathological 
condition due to the high expression level, then one can ask is there some 
other disease with similarly high expression level that could also be treated 
with the same drug. The bodywide expression profile of KIT is an example of 
this kind of drug repositioning. 
 
KIT is an interesting example also for the concept of transcriptional activity. 
As KIT is extremely highly expressed in GIST one can almost certainly assume 
that it is somehow active in that tissue. It does not allow for any assumption of 




assume that for some reason the gene’s expression is actively and positively 
upregulated in that tissue. This kind of thinking lead us to publication III, 
where we found that we can define the likely expression level above which the 
genes are under active and positive transcription regulation. In that study we 
defined which human kinase genes are transcriptionally active over 99 healthy 
and malignant human tissues. Furthermore, we found out that kinase genes 
are under so effective a transcriptional regulation that the major types of 
human tissues can be identified solely based on the binarized profiles of 
kinase gene transcriptional activities. As kinases are known to play an 
essential role in the signal transduction of cells at the protein level this 
effective level of transcriptional regulation was one of the key new findings of 
the publication III. 
 
The clustering of tissues based on transcriptionally active kinase genes 
revealed major clusters of solid healthy, hematological, solid malignancies and 
mixed clusters. Apart from the last-mentioned cluster, this is more or less 
similar to the division seen in the clustering made by using known cancer 
genes. Naturally the gene groups are partially overlapping but it is interesting 
to note that binarized expression profiles of kinase genes actually result in a 
more detailed clustering of cancers; even adeno and squamous types of 
cancers can be separated based on their kinase profiles. Our studies do not 
reveal whether this is mainly because kinases are important players in signal 
transduction and in malignant transformation or due to the noise reduction 
resulting from the binarization of the expression profiles. Additional analyses 
of clustering human tissues based on transcriptional activity levels of all genes 
support the fact that method provides accurate data across the entire genome. 
Therefore transcriptional activity levels could be used as foundation for 
further data mining. 
 
As the definition of transcriptional activity does not allow us to assume 
anything else except that the gene most likely is under active and positive 
transcription regulation we set out to also study the functional associations of 
the genes’ expression. This was done by forming a genomic coexpression 
network and subsequently finding which biological processes (GO-BP classes) 
were enriched in the vicinity of each kinase gene. These kinds of functional 
associations reveal if the expression of a kinase gene is correlated with the 
expression of group of genes all of which participate in the same biological 
processes and therefore, we could assume the kinase gene to be related into 
that process as well. Our results indicate that most kinase genes have rather 
clear associations to biological processes. The binarized expression profiles 
allowed us to make a rather straightforward comparative analysis of the 
kinase expression activity between healthy and malignant counterpart tissues 
by simply defining kinase genes whose transcriptional activity is lost or gained 
in malignant transformation. Functional associations allowed further 
understanding of what kind of biological processes are related into these 
changes. 
 
However, the relation between gene expression, actual function and activity of 
proteins is not always entirely linear. For deeper understanding of the human 
kinome there needs to be both protein level and activity measurements as well 




Comprehensive analysis of protein levels and activities across tissues on the 
scale similar to genome wide expression analyses is technologically much 
harder to perform. On the technological side newly developed protein lysate 
arrays, as described by Leivonen et al. [91], are providing more high-
throughput analysis of protein levels. However, large-scale kinase analyses 
with lysate arrays have yet to be performed. Other studies using more 
conventional immunohistochemistry (IHC) have been used to gather protein 
level data for increasing gene and tissue content. The most prominent of these 
studies is the human protein atlas described by Uhlen et al. [90]. They have 
profiled over 10 000 genes in terms of their protein levels over 46 normal 
human tissues and 20 cancer types. And as the protein levels do not correlate 
directly with the activity levels of proteins there is a need to separate protein 
activity screens. Various kinase activity profiling techniques are expertly 
reviewed by Johnson et al. [100]. 
 
On the side of functional screens Varjosalo et al. [99] cloned over 90% of full-
length protein kinase cDNAs. They also constructed corresponding kinase 
activity-deficient mutant cell lines that can be used further study the effect of 
the kinase on the signalling network of the cells. Kinases have also been 
subject to protein sequence level analysis by Manning et al. [97] revealing 
highly interesting hierarchy of structural similarities among kinases.  
 
Unforeseen understanding to the biology of human kinome might be achieved 
if data from i) DNA and protein sequence level analyses ii) transcriptomic 
analyses iii) protein level measurements iv) protein activity measurements v) 
results of functional screen could be fully integrated together. 
 
In publication IV we explored the expression value distributions of genes 
beyond the simple binary concept as we developed a method allowing the 
comparison of single sample in the context of large reference database. 
Essentially we wanted to enable an analysis option analogous to BLAST (used 
in the analysis of nucleotide sequences). The need for these kinds of methods 
is great as an individual expression profile is actually surprisingly difficult to 
interpret. Theoretically, existing collections of expression profiles in public 
databases should provide ample reference material, but there are not too 
many methods allowing this kind of comparisons and interpretations. 
Methods unveiled in publication IV show how one can form expression value 
estimates for each gene in each tissue and then use this information as the 
basis for comparing an individual expression profile to a large reference 
database. The AGEP method allows quantification of the similarity between a 
single query sample and the sample groups (e.g. tissues) in the reference 
database. This similarity in the transcriptomic program can then be explored 
at the level of genesets and genes. Overall, AGEP achieved at least as good a 
tissue classification accuracy as the most commonly used advanced classifier 
methods like support vector machine (SVM) or algorithmically simpler ones 
like nearest-neighbour (NN). It is not sensitive to missing values and in an 
elegant way can handle the heterogeneity of the samples forming a group (e.g. 
tissue), an issue that is always present when complex biological samples are 
annotated and grouped together. Drawback of the AGEP method is somewhat 





AGEP can be categorized as a search & retrieval type of a tool, able to 
relatively quickly to search through a database of gene expression profiles and 
retrieve profiles most similar to the query profile. These kinds of methods 
have just begun to emerge, thus there are not too many reasonably 
comparable to AGEP. Perhaps one of the most similar method is the gene 
expression barcode published by Zilliox et al. [107]. The methodology 
generates a barcode of active/deactive expression of genes for each tissue. 
Thus the barcode in its simplicity provides merely binary information whether 
the gene is expressed or not in the tissue in question. A query sample can then 
be compared against barcodes of the reference tissues and the sample can be 
classified with rather high accuracy (over 90% in several independent 
datasets) as reported by Zilliox et al.. This definition of active/deactive 
expression states is broadly similar approach than the one we used in 
publication III. It is interesting to note that both publications emphasize the 
same fact; binary gene expression profiles are highly robust and informative. 
 
An earlier related method has been reported by Parmigiani et al. [106], this 
statistical approach is broadly similar to the barcode method. The main 
difference between the two is that Parmigiani et al. considered genes in 
ternary mode (downregulated, normal and upregulated) when building a 
profile (analoguous to the barcode). These profiles can then be used to identify 
similarly behaving samples whether that similarity be a tissue classification or 
some other interesting property being studied. 
 
Another related study has been reported by Caldas et al. [109]. They describe 
another search & retrieval type of a method, probabilistic retrieval and 
visualization of biologically relevant microarray experiments, which is able to 
search for related experiments from a large collection of gene expression 
studies. However, direct comparison with the AGEP method is somewhat 
challenging. AGEP has been designed to compare a single sample against a 
reference database without any a priori assumptions about genes. The 
method described by Caldas et al. compare entire experiment to other 
experiments in the reference database and the measure of similarity is based 
on geneset enrichment instead of expression of individual genes. The method 
also uses median as a summary value of the expression across the samples, 
thereby not addressing the multimodality issue that AGEP was designed to 
take into account. 
 
One of the most interesting features of AGEP is that in the alignment of a 
query profile to the reference database one does not only get a similarity value 
for each reference sample class, but also a pair of values for each gene against 
each reference sample class. One of the values describes how well the 
expression of a gene matched the expected expression of the gene in a 
reference class in question and the other how unique this specific expression 
level of the reference sample class is. As the similarity to reference sample 
class is based on these values it is possible to understand how the similarity 
between query and reference class forms from the level of genes. Combining 
this with various paradigms of gene ontology or pathway style of gene 
annotation it is possible to uncover which biological processes component 
genes are expressed at typical level for which reference classes. For example, 




timepoint resemble the MSC reference class, but at the 7d timepoint they 
resemble the adipose tissue reference class. This change in transcriptomic 
program was further studied at the level of gene groups like one related to 
adipose tissue differentiation. At the 0h time point the genes of the group 
were expressed at level typical to MSC cells but at 7d timepoint they were 
expressed level typical to adipose tissue. Similarly, the change in the 
transcriptomic program was pointed at the level of individual genes as the 
genes with known role in adipose tissue gained adipose tissue specific 
expression level during the differentiation. 
 
One fundamental difference of AGEP to many other expression datamining 
approaches is that it does not emphasize overexpressed genes more than 
down expressed genes, but on the contrary, it forms a surprisingly robust 
estimate of the observed expression levels for each gene. Additionally, it does 
not make any a priori assumption of the informative genes. In other words, 
the presented way of understanding and using expression data treats each 
gene as an individual entity. Each gene has certain potential distribution of 
expression available to it in the collection of samples grouped together under 
the assumption that they are biologically at least semi-equivalent. If the 
grouped samples are heterogenous in terms of expression of certain gene (e.g. 
histologically defined breast ductal cancer and ERBB2 oncogene) then the 
distribution of potential expression values indeed is bimodal, as the gene in 
question can exist in two distinct expression states in the given population of 
samples. Given the heterogeneity of biological samples and the large number 
of genes it follows that practically all groups of samples will have some 
number of genes with bi- or multimodal expression distributions. 
 
The bi- or multimodality of gene expression levels leads to an interesting 
hypothesis, slightly explored in the publication III: Do some or all genes have 
discrete expression states more often than continuous distribution of 
expression activity? In other words, are the usually observed continuous 
expression value distributions there just because of noise in our sampling and 
measuring systems, or could the cells’ transcription regulation machinery 
actually be able to maintain more rigid control of the transcription? In the 
publication III we showed that the binarized expression states of human 
kinase genes seem to contain a great deal of information, and are able to 
reproduce large parts of the known and expected transcriptional behaviour of 
the genes. Thus it seems plausible to assume that at least for human kinase 
genes there are clearly two discrete states of expression. Results presented in 
Figure 8 and Figure 9 give supporting evidence that this could be true across 
the entire genome. Similarly, the study of Zilliox et al. [107] support the 
observation that it is possible to identify discrete expression states for all 
genes and the resulting data is accurate enough to perform tissue 
classification. In general, thresholding microarray data has been found to be a 
successful method as described by Shmulevich et al. and Pal et al. [159, 160]. 
Yet practically none of the existing studies touch deeply into the issue that is 
there more than two discrete states of expression. 
 
In publication IV we noticed that approximately 16% of genes present in the 
study had bi- or multimodal expression distribution. The method used to 




but it raises an interesting question. Does this 16% perhaps reflect a 
transcriptionally inconsistent sample grouping or could it be due to the cell’s 
capability of maintaining multiple discrete expression states for genes? 
Naturally, this falls back to the annotation and logic of grouping samples 
together as representative of a certain specific tissue. From the binarization of 
gene expression status we learned that large-scale expression data supports 
two discrete states of expression. It remains an open question how many 
discrete states there are and what is the biological relevance of these states. Is 
it possible to build model of human transcriptome with multiple distinct 
‘digital’ expression states for all genes across all tissues?  Currently there are 
no studies properly addressing this issue, at least in the context of entire 
human transcriptome in hundreds of tissue types, but for certain such studies 
will be performed. 
 
The ability to find expression based biomarkers, drug repositioning, 
identification of patient subgroups, exploration of expression activity of genes 
across wide spectrum of healthy and pathological tissues, functional 
associations through co-expression environment, interpreting individual 
expression profiles and construction of comprehensive models of human 
transcriptome have all in common the fact that they require large amounts of 
unified and integrated expression data. Data needs to be acquired and 
compiled together from multiple sources. In its entirety, the human 
transcriptome across healthy and pathological tissues is far too massive to be 
analysed in any single experiment. 
 
Conclusions and future prospects 
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10. Conclusions and future prospects 
GeneSapiens contains manually curated annotation for 9873 in vivo samples 
with as complete clinical information as available, thus comprising the largest 
fully integrated gene expression database. It has been constructed by using 
solely Affymetrix microarrays, which are generally known to be very reliable 
and robust [7]. As pointed out by the MAQC study [5, 6] Affymetrix arrays 
have the best interlaboratory reproducibility. Additionally, GeneSapiens uses 
custom normalization designed to lower technical noise from various 
Affymetrix chip generations as well as uses state-of-the-art probe mapping 
[70] also pointed out by the MAQC study to be an important factor in 
reliability. A GeneSapiens type of resources can be used in understanding 
otherwise difficult to interpret expression values in both gene and sample 
dimensions. In the gene dimension one can identify tissues and/or 
pathologies where the gene is actively expressed or which genes are its co-
expression partners. This is useful for multiple applications like basic research 
of gene functions, biomarker identification and drug repositioning as it 
provides a comprehensive “map” of gene expression activity across major 
portion of human tissues. On the sample dimension GeneSapiens data allows 
unforeseen possibilities to understand and interpret unknown or novel 
expression profiles. This line of thought has interesting consequences in the 
field of personalized oncology, the comparison of an expression profile from a 
patient’s tumor against both healthy and pathological references could allow 
interpretation and understanding the expression level anomalies present in 
the tumor. 
 
Methods like AGEP might provide a robust way to characterize all the 
expression anomalies of a patient’s tumor in comparison to healthy reference. 
Furthermore, the robust ability to effectively compare a patient to a reference 
collection of thousands of patient profiles can situate the patient into the 
correct disease subtype and pinpoint expression anomalies that are personal 
to the patient in question. In theory these kinds of abilities could be used to 
prioritize treatment decisions on a truly personal level. 
 
In overall, transcriptome research and meta-analysis should go towards more 
comprehensive modeling of the entire transcriptome. Even though 
GeneSapiens represents the most advanced fully integrated human 
transcriptomics database and can therefore push the research forward, the 
ramifications of deeper understanding of the structure and function of the 
transcriptome, as shown by Frith et al. [29] and Gingeras et al. [39] as well as 
the new possibilities opened by next-generation sequencing technologies, are 
already shaking the foundations functional genomics. At best, a gene and its 
measured expression level is only a suggestive model of the expression of the 
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